<!DOCTYPE html>
<html lang="en" dir="ltr" 
  xmlns="http://www.w3.org/1999/xhtml"
  xmlns:mml="http://www.w3.org/1998/Math/MathML">
  <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#" >
    <!--[if IE]><![endif]-->
<link rel="dns-prefetch" href="//d33xdlntwy0kbs.cloudfront.net" />
<link rel="dns-prefetch" href="//www.google.com" />
<link rel="dns-prefetch" href="//scholar.google.com" />
<link rel="dns-prefetch" href="//www.google-analytics.com" />
<link rel="dns-prefetch" href="//stats.g.doubleclick.net" />
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<link rel="shortcut icon" href="https://www.medrxiv.org/sites/default/files/images/favicon.ico" type="image/vnd.microsoft.icon" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link rel="alternate" type="application/pdf" title="Full Text (PDF)" href="/content/10.1101/2021.10.24.21265450v1.full.pdf" />
<link rel="alternate" type="text/plain" title="Full Text (Plain)" href="/content/10.1101/2021.10.24.21265450v1.full.txt" />
<meta name="type" content="article" />
<meta name="category" content="article" />
<meta name="HW.identifier" content="/medrxiv/early/2021/10/26/2021.10.24.21265450.atom" />
<meta name="HW.pisa" content="medrxiv;2021.10.24.21265450v1" />
<meta name="DC.Format" content="text/html" />
<meta name="DC.Language" content="en" />
<meta name="DC.Title" content="Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review" />
<meta name="DC.Identifier" content="10.1101/2021.10.24.21265450" />
<meta name="DC.Date" content="2021-10-26" />
<meta name="DC.Publisher" content="Cold Spring Harbor Laboratory Press" />
<meta name="DC.Rights" content="© 2021, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NoDerivs 4.0 International), CC BY-ND 4.0, as described at http://creativecommons.org/licenses/by-nd/4.0/" />
<meta name="DC.AccessRights" content="restricted" />
<meta name="DC.Description" content="Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the currently approved CAR T-cell therapies. In the absence of head-to-head comparisons and randomized controlled trials, we performed Matching Adjusted Indirect Comparisons to quantify the relative efficacy and safety of experimental CARs against Axicabtagene ciloleucel (Yescarta), the first FDA-approved CAR. A total of 182 R/R LBCL patients from 15 clinical trials with individual patient data (IPD) were pooled into eight populations by their CAR T-cell constructs and +/-ASCT status. The study endpoints were Progression-Free Survival (PFS), grade ≥ 3 cytokine release syndrome (CRS), and grade ≥ 3 neurotoxicity (NT). Tandem CD19.CD20.4-1BBζ CARs indicated favorable ef?cacy and safety, whereas the co-infusion of CD19 &amp; CD20 with 4-1BBζ showed no clinical benefit compared to Yescarta. Third generation CD19. CD28. 4-1BBζ, and sequential administration of autologous stem cell transplantation (ASCT) and CD19. CARs presented statistically insignificant yet improved PFS and safety except for ASCT combined intervention which had suggestively higher NT risk than Yescarta. CARs with modified co-stimulatory domains to reduce toxicity (Hu19. CD8.28Zζ and CD19. BBz.86ζ) presented remarkable safety with no severe adverse events; however, both presented worse PFS than Yescarta. Third-generation CARs demonstrated statistically significantly lower NT than Yescarta. CD20. 4-1BBζ data suggested targeting CD20 antigen alone lacks clinical or safety benefit compared to Yescarta. Further comparisons with other FDA-approved CARs are needed.

NOVELTY AND IMPACT Although currently approved CAR T-cells demonstrated unprecedently high response in relapsed / refractory LBCL in the salvage setting, lack of outcome durability and toxicity remain. We delineated the relative clinical benefit of the innovative experimental CAR T-cell approaches to Yescarta for insights into the ongoing efforts to address these inadequacies. Tandem CAR T-cells may provide higher efficacy and safer profile than Yescarta. Toxicity attenuated CAR T-cells present remarkable safety but no Progression-Free Survival (PFS) benefit.

### Competing Interest Statement

The authors have declared no competing interest.

### Clinical Protocols

&lt;https://journal.ppcr.org/index.php/ppcrjournal/article/view/142&gt; 

### Funding Statement

This study did not receive any funding

### Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was based on the published data by the eligible clinical trials in this study. Therefore, ethics committee approval or informed consent statement were not required since the study did not involve patients or the public in the design, conduct, reporting, or dissemination plans. 

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Individual patient data obtained from the eligible clinical trials analyzed in this study and any materials generated during the study are available and will be released via a material transfer agreement and study protocol, if available.

&lt;https://journal.ppcr.org/index.php/ppcrjournal/article/view/142&gt; 

*   ASCT
    :   autologous stem cell transplantation
    B-ALL
    :   B-cell acute lymphoblastic leukemia
    BCMA
    :   B-cell maturation antigen
    CAR
    :   chimeric antigen receptor
    CD
    :   cluster of differentiation
    ChiCTR
    :   Chinese clinical trial registry
    CI
    :   confidence interval
    CR
    :   complete response
    CRES
    :   car T cell-related encephalopathy syndrome
    CRR
    :   complete response rate
    CRS
    :   cytokine release syndrome
    CRS
    :   cytokine release syndrome
    DLBCL
    :   diffuse large B-cell lymphoma
    DOR
    :   duration of response
    EFS
    :   event-free survival
    ESS
    :   effective sample size
    HGBCL
    :   high-grade B-cell lymphoma
    HR
    :   hazard ratio
    Hu
    :   human
    IFN-γ
    :   interferon-γ
    IL-2
    :   interleukins-2
    IPD
    :   individual patient data
    KM
    :   Kaplan-Meier
    LBCL
    :   large B-cell lymphoma
    MAIC
    :   matching adjusted indirect comparisons
    NCT
    :   national clinical trial
    NHL
    :   non-Hodgkin lymphoma
    NT
    :   neurotoxicity
    OR
    :   odds ratio
    ORR
    :   objective response rate
    OS
    :   overall survival
    PFS
    :   progression free survival
    PH
    :   proportional hazards
    PPCR
    :   principles and practice of clinical research
    PRISMA
    :   preferred reporting items for systematic reviews and meta-analyses
    R/R LBCL
    :   relapsed/refractory large B-cell lymphoma
    RR
    :   relative risk
    RS
    :   Richter’s transformation
    scFv
    :   single-chain variable fragment
    SD
    :   stable disease
    TNF-α
    :   tumor necrosis factor-α
    trDLBCL
    :   transformed DLBCL
    ZUMA-1
    :   name of Yescarta clinical trial" />
<meta name="DC.Contributor" content="Bayarmagnai Weinstein" />
<meta name="DC.Contributor" content="Bogdan Muresan" />
<meta name="DC.Contributor" content="Sara Solano" />
<meta name="DC.Contributor" content="Antonio Vaz de Macedo" />
<meta name="DC.Contributor" content="YoonJung Lee" />
<meta name="DC.Contributor" content="Yu-Chen Su" />
<meta name="DC.Contributor" content="Yeseul Ahn" />
<meta name="DC.Contributor" content="Gabriela Henriquez" />
<meta name="DC.Contributor" content="Cristina Camargo" />
<meta name="DC.Contributor" content="Gwang-Jin Kim" />
<meta name="DC.Contributor" content="David O. Carpenter" />
<meta name="article:published_time" content="2021-10-26" />
<meta name="citation_title" content="Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review" />
<meta name="citation_abstract" lang="en" content="&lt;p&gt;Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the currently approved CAR T-cell therapies. In the absence of head-to-head comparisons and randomized controlled trials, we performed Matching Adjusted Indirect Comparisons to quantify the relative efficacy and safety of experimental CARs against Axicabtagene ciloleucel (Yescarta), the first FDA-approved CAR. A total of 182 R/R LBCL patients from 15 clinical trials with individual patient data (IPD) were pooled into eight populations by their CAR T-cell constructs and +/- ASCT status. The study endpoints were Progression-Free Survival (PFS), grade ≥ 3 cytokine release syndrome (CRS), and grade ≥ 3 neurotoxicity (NT). Tandem CD19.CD20.4-1BBζ CARs indicated favorable efﬁcacy and safety, whereas the co-infusion of CD19 &amp;amp; CD20 with 4-1BBζ showed no clinical benefit compared to Yescarta. Third generation CD19. CD28. 4-1BBζ, and sequential administration of autologous stem cell transplantation (ASCT) and CD19. CARs presented statistically insignificant yet improved PFS and safety except for ASCT combined intervention which had suggestively higher NT risk than Yescarta. CARs with modified co-stimulatory domains to reduce toxicity (Hu19. CD8.28Zζ and CD19. BBz.86ζ) presented remarkable safety with no severe adverse events; however, both presented worse PFS than Yescarta. Third-generation CARs demonstrated statistically significantly lower NT than Yescarta. CD20. 4-1BBζ data suggested targeting CD20 antigen alone lacks clinical or safety benefit compared to Yescarta. Further comparisons with other FDA-approved CARs are needed.&lt;/p&gt;" />
<meta name="citation_journal_title" content="medRxiv" />
<meta name="citation_publisher" content="Cold Spring Harbor Laboratory Press" />
<meta name="citation_publication_date" content="2021/01/01" />
<meta name="citation_mjid" content="medrxiv;2021.10.24.21265450v1" />
<meta name="citation_id" content="2021.10.24.21265450v1" />
<meta name="citation_public_url" content="https://www.medrxiv.org/content/10.1101/2021.10.24.21265450v1" />
<meta name="citation_abstract_html_url" content="https://www.medrxiv.org/content/10.1101/2021.10.24.21265450v1.abstract" />
<meta name="citation_full_html_url" content="https://www.medrxiv.org/content/10.1101/2021.10.24.21265450v1.full" />
<meta name="citation_pdf_url" content="https://www.medrxiv.org/content/medrxiv/early/2021/10/26/2021.10.24.21265450.full.pdf" />
<meta name="citation_doi" content="10.1101/2021.10.24.21265450" />
<meta name="citation_num_pages" content="25" />
<meta name="citation_article_type" content="Article" />
<meta name="citation_firstpage" content="2021.10.24.21265450" />
<meta name="citation_author" content="Bayarmagnai Weinstein" />
<meta name="citation_author_institution" content="Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health" />
<meta name="citation_author_institution" content="Department of Environmental Health Sciences, School of Public Health, University at Albany" />
<meta name="citation_author_email" content="bmunkhjargal@albany.edu" />
<meta name="citation_author_orcid" content="http://orcid.org/0000-0001-9572-7349" />
<meta name="citation_author" content="Bogdan Muresan" />
<meta name="citation_author_institution" content="Health Sciences Unit, University of Groningen, University Medical Center Groningen" />
<meta name="citation_author" content="Sara Solano" />
<meta name="citation_author_institution" content="Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health" />
<meta name="citation_author" content="Antonio Vaz de Macedo" />
<meta name="citation_author_institution" content="Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health" />
<meta name="citation_author_institution" content="Hematology Clinic, Hospital da Polícia Militar" />
<meta name="citation_author" content="YoonJung Lee" />
<meta name="citation_author_institution" content="Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center" />
<meta name="citation_author" content="Yu-Chen Su" />
<meta name="citation_author_institution" content="Inari Medical, Biostatistics and Programming Dept" />
<meta name="citation_author" content="Yeseul Ahn" />
<meta name="citation_author_institution" content="Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center" />
<meta name="citation_author" content="Gabriela Henriquez" />
<meta name="citation_author_institution" content="Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health" />
<meta name="citation_author_institution" content="Iberoamerican University" />
<meta name="citation_author" content="Cristina Camargo" />
<meta name="citation_author_institution" content="School of Medicine, Univesida de São Paulo" />
<meta name="citation_author" content="Gwang-Jin Kim" />
<meta name="citation_author_institution" content="Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg" />
<meta name="citation_author" content="David O. Carpenter" />
<meta name="citation_author_institution" content="Department of Environmental Health Sciences, School of Public Health, University at Albany" />
<meta name="citation_author_institution" content="Institute for Health and the Environment, University at Albany" />
<meta name="citation_reference" content="Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood [Internet]. 2006;107(1):265–76. Available from: /pmc/articles/PMC1895348/" />
<meta name="citation_reference" content="Howlader N, Noon AM KM. Cancer Statistics Review, 1975-2013 - Previous Version - SEER Cancer Statistics Review [Internet]. 2015 [cited 2021 Jun 9]. Available from: https://seer.cancer.gov/archive/csr/1975_2013/" />
<meta name="citation_reference" content="Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. [Internet]. Vol. 2011, Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. Hematology Am Soc Hematol Educ Program; 2011. p. 498–505. Available from: https://pubmed.ncbi.nlm.nih.gov/22160081/" />
<meta name="citation_reference" content="Neste E Van Den, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant [Internet]. 2016;51(1):51–7. Available from: https://pubmed.ncbi.nlm.nih.gov/26367239/" />
<meta name="citation_reference" content="Gisselbrecht C, Schmitz N, Mounier N, Gill DS, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: Final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol [Internet]. 2012;30(36):4462–9. Available from: https://pubmed.ncbi.nlm.nih.gov/23091101/" />
<meta name="citation_reference" content="Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 Sep 19;396(10254):839–52." />
<meta name="citation_reference" content="Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med [Internet]. 2017 Dec 28 [cited 2021 May 13];377(26):2531–44. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1707447" />
<meta name="citation_reference" content="Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med [Internet]. 2019 Jan 3 [cited 2021 Jun 9];380(1):45–56. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1804980" />
<meta name="citation_reference" content="Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019 Jan 1;20(1):31–42." />
<meta name="citation_reference" content="Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016 Oct 3;126(10):3814–26." />
<meta name="citation_reference" content="Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature [Internet]. 2019 Apr 4 [cited 2021 Jun 2];568(7750):112–6. Available from: https://pubmed.ncbi.nlm.nih.gov/30918399/" />
<meta name="citation_reference" content="Shah NN, Maatman T, Hari P, Johnson B. Multi targeted CAR-T cell therapies for B-cell malignancies. Front Oncol. 2019;9(MAR):1–7." />
<meta name="citation_reference" content="Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini RM, et al. A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24(24):6185–94." />
<meta name="citation_reference" content="Huang C, Wu L, Liu R, Li W, Li Z, Li J, et al. Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study. Ann Transl Med Vol 8, No 17 (September 2020) Ann Transl Med [Internet]. 2020; Available from: http://atm.amegroups.com/article/view/49940" />
<meta name="citation_reference" content="Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. In Vivo Fate and Activity of Second-versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas. Mol Ther. 2018 Dec 5;26(12):2727–37." />
<meta name="citation_reference" content="Brudno JN, Lam N, Vanasse D, Shen Y wei, Rose JJ, Rossi J, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med [Internet]. 2020 Feb 1 [cited 2020 Nov 10];26(2):270–80. Available from: https://doi.org/10.1038/s41591-019-0737-3" />
<meta name="citation_reference" content="Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med [Internet]. 2019 Jun 1 [cited 2020 Nov 18];25(6):947–53. Available from: https://www-nature-com.libproxy.albany.edu/articles/s41591-019-0421-7" />
<meta name="citation_reference" content="Cao Y, Lu W, Sun R, Jin X, Cheng L, He X, et al. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma. Front Oncol [Internet]. 2019 Aug 19 [cited 2020 Nov 25];9(AUG):767. Available from: https://www.frontiersin.org/article/10.3389/fonc.2019.00767/full" />
<meta name="citation_reference" content="Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, et al. Phase i trials using sleeping beauty to generate CD19-specific CAR T cells. J Clin Invest [Internet]. 2016 Sep 1 [cited 2020 Oct 15];126(9):3363–76. Available from: www.imgt.org/" />
<meta name="citation_reference" content="Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, et al. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood [Internet]. 2019 Aug [cited 2020 Oct 15];134(7):626–35. Available from: https://pubmed.ncbi.nlm.nih.gov/31262783/" />
<meta name="citation_reference" content="Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood [Internet]. 2016 Jun 16 [cited 2020 Oct 15];127(24):2980–90. Available from: http://ashpublications.org/blood/article-pdf/127/24/2980/1394503/2980.pdf" />
<meta name="citation_reference" content="Schneider D, Xiong Y, Wu D, Hu P, Alabanza L, Steimle B, et al. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci Transl Med [Internet]. 2021 Mar 24 [cited 2021 May 23];13(586). Available from: https://stm.sciencemag.org/content/13/586/eabc6401" />
<meta name="citation_reference" content="Schneider D, Xiong Y, Wu D, Nölle V, Schmitz S, Haso W, et al. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J Immunother Cancer. 2017;5(1):1–17." />
<meta name="citation_reference" content="Zah E, Lin MY, Anne SB, Jensen MC, Chen YY. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res [Internet]. 2016 Jun 1 [cited 2021 May 13];4(6):498–508. Available from: https://www.aacrjournals.org" />
<meta name="citation_reference" content="Ormhøj M, Scarfo I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, et al. Chimeric antigen receptor T cells targetin CD79b show efficacy in lymphoma with or without cotargeting CD19. Clin Cancer Res [Internet]. 2019 Dec 1 [cited 2021 May 13];25(23):7046–57. Available from: http://clincancerres.aacrjournals.org/" />
<meta name="citation_reference" content="Mihara K, Yanagihara K, Takigahira M, Kitanaka A, Imai C, Bhattacharyya J, et al. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma. Br J Haematol [Internet]. 2010 Oct 1 [cited 2021 May 13];151(1):37–46. Available from: http://symatlas.gnf.org" />
<meta name="citation_reference" content="Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, et al. Anti-CD37 chimeric antigen receptor T cells are active against B-A nd T-cell lymphomas. Blood [Internet]. 2018 Oct 4 [cited 2021 May 13];132(14):1495–506. Available from: http://ashpublications.org/blood/article-pdf/132/14/1495/1727274/blood842708.pdf" />
<meta name="citation_reference" content="Zhang Y. Safety and efficacy of optimized tandem CD19/CD20 CAR-engineered T cells in patients with relapsed/refractory non-Hodgkin lymphoma. J Clin Oncol. 2020 May 20;38(15_suppl):3034–3034." />
<meta name="citation_reference" content="Tong C, Zhang Y, Liu Y, Ji X, Zhang W-Y, Guo Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. Blood [Internet]. 2020;((Tong C.; Zhang Y.; Liu Y.; Han X.; Ti D.; Wang C.; Wu Z.; Han W.) Chinese PLA General Hospital, China). Available from: https://www.embase.com/search/results?subaction=viewrecord&amp;id=L632129081&amp;from=export" />
<meta name="citation_reference" content="Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569–75." />
<meta name="citation_reference" content="Sang W, Shi M, Yang J, Cao J, Xu L, Yan D, et al. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med. 2020 Jul;9(16):5827–38." />
<meta name="citation_reference" content="Zeng C, Cheng J, Li T, Huang J, Li C, Jiang L, et al. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy. 2020 Mar 1;22(3):166–71." />
<meta name="citation_reference" content="Wang N, Hu X, Cao W, Li C, Xiao Y, Cao Y, et al. Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. Blood [Internet]. 2020 Jan 2 [cited 2021 May 13];135(1):17–27. Available from: www.chictr.org.cn" />
<meta name="citation_reference" content="Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI 3 kinase/AKT/Bcl-X L activation and CD8 T cell-mediated tumor eradication. Mol Ther. 2010 Feb 1;18(2):413–20." />
<meta name="citation_reference" content="Li C, Zhang Y, Zhang C, Chen J, Lou X, Chen X, et al. Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin’s lymphoma. JCI Insight [Internet]. 2019 Aug 22 [cited 2021 May 20];4(17). Available from: /pmc/articles/PMC6777912/" />
<meta name="citation_reference" content="Wang Y, Zhang W ying, Han Q wang, Liu Y, Dai Hren, Guo Y lei, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 2014 Dec 1;155(2):160–75." />
<meta name="citation_reference" content="Zhang WY, Liu Y, Wang Y, Wang CM, Yang QM, Zhu HL, et al. Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed b-cell non-hodgkin lymphoma: 5-years follow-up results of the phase i and iia trials. Signal Transduct Target Ther. 2017;2:0–3." />
<meta name="citation_reference" content="Zhang WY, Wang Y, Guo YL, Dai HR, Yang QM, Zhang YJ, et al. Treatment of cd20-directed chimeric antigen receptor-modified t cells in patients with relapsed or refractory b-cell non-hodgkin lymphoma: An early phase iia trial report. Signal Transduct Target Ther. 2016;1(January):1–9." />
<meta name="citation_reference" content="Borchmann P. Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. ASH; 2020." />
<meta name="citation_reference" content="Shadman M, Gopal AK, Smith SD, Lynch RC, Ujjani CS, Turtle CJ, et al. CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas. Blood. 2019 Nov 13;134(Supplement_1):3235–3235." />
<meta name="citation_reference" content="Salles G, Barrett M, Foà R, Maurer J, O’Brien S, Valente N, et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [Internet]. Vol. 34, Advances in Therapy. Springer Healthcare; 2017 [cited 2021.May 22]. p. 2232–73. Available from: http://www.medengine.com/Redeem/" />
<meta name="citation_reference" content="Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal. Med Decis Mak. 2018 Feb 1;38(2):200–11." />
<meta name="citation_reference" content="Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: A new tool for timely comparative effectiveness research. Value Heal. 2012 Sep 1;15(6):940–7." />
<meta name="citation_reference" content="NIH. Study Quality Assessment Tools | NHLBI, NIH [Internet]. NIH. 2013 [cited 2021 Oct 24]. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools" />
<meta name="citation_reference" content="Weinstein B, Muresan B, Solano S, Vaz de Macedo A, Lee Y. Efficacy and Safety of Experimental versus Approved CAR T-cell Therapies in Large B-cell Lymphoma Using Matching Adjusted Indirect Comparisons: A. journal.ppcr.org [Internet]. [cited 2021 Jun 9]; Available from: https://journal.ppcr.org/index.php/ppcrjournal/article/view/142" />
<meta name="citation_reference" content="Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol [Internet]. 2012 Feb 1 [cited 2021 Jun 9];12(1):1–13. Available from: https://link.springer.com/articles/10.1186/1471-2288-12-9" />
<meta name="citation_reference" content="Oluwole OO, Jansen JP, Lin VW, Chan K, Keeping S, Navale L, et al. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma: Comparative Study of Axicabtagene Ciloleucel and Tisagenlecleucel. Biol Blood Marrow Transplant [Internet]. 2020 Sep 1 [cited 2021 May 2];26(9):1581–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32561336/" />
<meta name="citation_reference" content="Chen X, Li X, Liu Y, Zhang Z, Zhang X, Huang J, et al. A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. Immunotherapy. 2020 Jul 1;12(10):681–96." />
<meta name="citation_reference" content="Wang T, Gao L, Wang Y, Zhu W, Xu L, Wang Y, et al. Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma. Immunotherapy [Internet]. 2020 Sep 1 [cited 2020 Oct 15];12(13):997–1006. Available from: https://www.futuremedicine.com/doi/abs/10.2217/imt-2020-0075" />
<meta name="citation_reference" content="Guo Z, Tu S, Yu S, Wu L, Pan W, Chang N, et al. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies [Internet]. Vol. 112, Cancer Science. Blackwell Publishing Ltd; 2021 [cited 2021 May 14]. p. 1357–68. Available from: /pmc/articles/PMC8019219/" />
<meta name="citation_reference" content="Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol [Internet]. 2019;16(6):372–85. Available from: http://dx.doi.org/10.1038/s41571-019-0184-6" />
<meta name="citation_reference" content="Hossain N, Sahaf B, Abramian M, Spiegel JY, Kong K, Kim S, et al. Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies. Blood. 2018 Nov 29;132(Supplement 1):490–490." />
<meta name="citation_reference" content="Amrolia PJ, Wynn R, Hough RE, Vora A, Bonney D, Veys P, et al. Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study. Blood. 2019 Nov 13;134(Supplement_1):2620–2620." />
<meta name="citation_reference" content="Yang J, Li J, Zhang X, Lv F, Guo X, Wang Q, et al. A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia. Blood. 2018 Nov 29;132(Supplement 1):277–277." />
<meta name="citation_reference" content="Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A [Internet]. 2009 Mar 3 [cited 2021 May 16];106(9):3360– 5. Available from: https://pubmed.ncbi.nlm.nih.gov/19211796/" />
<meta name="citation_reference" content="Gomes-Silva D, Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, et al. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct;21(1):17–26." />
<meta name="citation_reference" content="Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med [Internet]. 2019 Jan 1 [cited 2021 May 20];25(1):82–8. Available from: https://pubmed.ncbi.nlm.nih.gov/30559421/" />
<meta name="citation_reference" content="Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the antigen density requirement for car T-cell activity. Cancer Discov [Internet]. 2020 May 1 [cited 2021 May 20];10(5):702–23. Available from: http://cancerdiscovery.aacrjournals.org/" />
<meta name="citation_reference" content="Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin’s Lymphoma. N Engl J Med [Internet]. 1995 Dec 7 [cited 2021 May 21];333(23):1540–5. Available from: https://pubmed.ncbi.nlm.nih.gov/7477169/" />
<meta name="citation_reference" content="June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med [Internet]. 2018 Jul 5 [cited 2021 May 23];379(1):64–73. Available from: http://www.nejm.org/doi/10.1056/NEJMra1706169" />
<meta name="citation_reference" content="Horna P, Nowakowski G, Endell J, Boxhammer R. Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies. Blood. 2019 Nov 13;134(Supplement_1):5345–5345." />
<meta name="citation_reference" content="Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey [Internet]. Vol. 25, Nature Medicine. Nature Publishing Group; 2019 [cited 2021 May 17]. p. 1341–55. Available from: https://www-nature-com.libproxy.albany.edu/articles/s41591-019-0564-6" />
<meta name="citation_reference" content="Maloney DG, Kuruvilla J, Fox CP, Cartron G, Li D, Hasskarl J, et al. Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL). Blood. 2020 Nov 5;136(Supplement 1):18–9." />
<meta name="citation_reference" content="Ramsborg CG, Guptill P, Weber C, Christin B, Larson RP, Lewis K, et al. JCAR017 Is a Defined Composition CAR T Cell Product with Product and Process Controls That Deliver Precise Doses of CD4 and CD8 CAR T Cell to Patients with NHL. Blood. 2017 Dec 7;130(Supplement 1):4471–4471." />
<meta name="citation_reference" content="Vo TT, Porcher R, Chaimani A, Vansteelandt S. A novel approach for identifying and addressing case-mix heterogeneity in individual participant data meta-analysis. Res Synth Methods [Internet]. 2019 Dec 1 [cited 2021 Jun 14];10(4):582–96. Available from: https://pubmed.ncbi.nlm.nih.gov/31682071/" />
<meta name="citation_reference" content="Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Vol. 25, Biology of Blood and Marrow Transplantation. Elsevier Inc.; 2019. p. 625–38." />
<meta name="citation_reference" content="Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 2018 245 [Internet]. 2018 Apr 30 [cited 2021 Oct 24];24(5):563–71. Available from: https://www.nature.com/articles/s41591-018-0010-1" />
<meta name="citation_reference" content="Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 2018 369 [Internet]. 2018 Oct 1 [cited 2021 Oct 24];36(9):847–56. Available from: https://www.nature.com/articles/nbt.4195" />
<meta name="twitter:title" content="Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review" />
<meta name="twitter:site" content="@medrxivpreprint" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:description" content="Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the currently approved CAR T-cell therapies. In the absence of head-to-head comparisons and randomized controlled trials, we performed Matching Adjusted Indirect Comparisons to quantify the relative efficacy and safety of experimental CARs against Axicabtagene ciloleucel (Yescarta), the first FDA-approved CAR. A total of 182 R/R LBCL patients from 15 clinical trials with individual patient data (IPD) were pooled into eight populations by their CAR T-cell constructs and +/-ASCT status. The study endpoints were Progression-Free Survival (PFS), grade ≥ 3 cytokine release syndrome (CRS), and grade ≥ 3 neurotoxicity (NT). Tandem CD19.CD20.4-1BBζ CARs indicated favorable ef?cacy and safety, whereas the co-infusion of CD19 &amp; CD20 with 4-1BBζ showed no clinical benefit compared to Yescarta. Third generation CD19. CD28. 4-1BBζ, and sequential administration of autologous stem cell transplantation (ASCT) and CD19. CARs presented statistically insignificant yet improved PFS and safety except for ASCT combined intervention which had suggestively higher NT risk than Yescarta. CARs with modified co-stimulatory domains to reduce toxicity (Hu19. CD8.28Zζ and CD19. BBz.86ζ) presented remarkable safety with no severe adverse events; however, both presented worse PFS than Yescarta. Third-generation CARs demonstrated statistically significantly lower NT than Yescarta. CD20. 4-1BBζ data suggested targeting CD20 antigen alone lacks clinical or safety benefit compared to Yescarta. Further comparisons with other FDA-approved CARs are needed.

NOVELTY AND IMPACT Although currently approved CAR T-cells demonstrated unprecedently high response in relapsed / refractory LBCL in the salvage setting, lack of outcome durability and toxicity remain. We delineated the relative clinical benefit of the innovative experimental CAR T-cell approaches to Yescarta for insights into the ongoing efforts to address these inadequacies. Tandem CAR T-cells may provide higher efficacy and safer profile than Yescarta. Toxicity attenuated CAR T-cells present remarkable safety but no Progression-Free Survival (PFS) benefit.

### Competing Interest Statement

The authors have declared no competing interest.

### Clinical Protocols

&lt;https://journal.ppcr.org/index.php/ppcrjournal/article/view/142&gt; 

### Funding Statement

This study did not receive any funding

### Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was based on the published data by the eligible clinical trials in this study. Therefore, ethics committee approval or informed consent statement were not required since the study did not involve patients or the public in the design, conduct, reporting, or dissemination plans. 

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Individual patient data obtained from the eligible clinical trials analyzed in this study and any materials generated during the study are available and will be released via a material transfer agreement and study protocol, if available.

&lt;https://journal.ppcr.org/index.php/ppcrjournal/article/view/142&gt; 

*   ASCT
    :   autologous stem cell transplantation
    B-ALL
    :   B-cell acute lymphoblastic leukemia
    BCMA
    :   B-cell maturation antigen
    CAR
    :   chimeric antigen receptor
    CD
    :   cluster of differentiation
    ChiCTR
    :   Chinese clinical trial registry
    CI
    :   confidence interval
    CR
    :   complete response
    CRES
    :   car T cell-related encephalopathy syndrome
    CRR
    :   complete response rate
    CRS
    :   cytokine release syndrome
    CRS
    :   cytokine release syndrome
    DLBCL
    :   diffuse large B-cell lymphoma
    DOR
    :   duration of response
    EFS
    :   event-free survival
    ESS
    :   effective sample size
    HGBCL
    :   high-grade B-cell lymphoma
    HR
    :   hazard ratio
    Hu
    :   human
    IFN-γ
    :   interferon-γ
    IL-2
    :   interleukins-2
    IPD
    :   individual patient data
    KM
    :   Kaplan-Meier
    LBCL
    :   large B-cell lymphoma
    MAIC
    :   matching adjusted indirect comparisons
    NCT
    :   national clinical trial
    NHL
    :   non-Hodgkin lymphoma
    NT
    :   neurotoxicity
    OR
    :   odds ratio
    ORR
    :   objective response rate
    OS
    :   overall survival
    PFS
    :   progression free survival
    PH
    :   proportional hazards
    PPCR
    :   principles and practice of clinical research
    PRISMA
    :   preferred reporting items for systematic reviews and meta-analyses
    R/R LBCL
    :   relapsed/refractory large B-cell lymphoma
    RR
    :   relative risk
    RS
    :   Richter’s transformation
    scFv
    :   single-chain variable fragment
    SD
    :   stable disease
    TNF-α
    :   tumor necrosis factor-α
    trDLBCL
    :   transformed DLBCL
    ZUMA-1
    :   name of Yescarta clinical trial" />
<meta name="og-title" property="og:title" content="Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review" />
<meta name="og-url" property="og:url" content="https://www.medrxiv.org/content/10.1101/2021.10.24.21265450v1" />
<meta name="og-site-name" property="og:site_name" content="medRxiv" />
<meta name="og-description" property="og:description" content="Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the currently approved CAR T-cell therapies. In the absence of head-to-head comparisons and randomized controlled trials, we performed Matching Adjusted Indirect Comparisons to quantify the relative efficacy and safety of experimental CARs against Axicabtagene ciloleucel (Yescarta), the first FDA-approved CAR. A total of 182 R/R LBCL patients from 15 clinical trials with individual patient data (IPD) were pooled into eight populations by their CAR T-cell constructs and +/-ASCT status. The study endpoints were Progression-Free Survival (PFS), grade ≥ 3 cytokine release syndrome (CRS), and grade ≥ 3 neurotoxicity (NT). Tandem CD19.CD20.4-1BBζ CARs indicated favorable ef?cacy and safety, whereas the co-infusion of CD19 &amp; CD20 with 4-1BBζ showed no clinical benefit compared to Yescarta. Third generation CD19. CD28. 4-1BBζ, and sequential administration of autologous stem cell transplantation (ASCT) and CD19. CARs presented statistically insignificant yet improved PFS and safety except for ASCT combined intervention which had suggestively higher NT risk than Yescarta. CARs with modified co-stimulatory domains to reduce toxicity (Hu19. CD8.28Zζ and CD19. BBz.86ζ) presented remarkable safety with no severe adverse events; however, both presented worse PFS than Yescarta. Third-generation CARs demonstrated statistically significantly lower NT than Yescarta. CD20. 4-1BBζ data suggested targeting CD20 antigen alone lacks clinical or safety benefit compared to Yescarta. Further comparisons with other FDA-approved CARs are needed.

NOVELTY AND IMPACT Although currently approved CAR T-cells demonstrated unprecedently high response in relapsed / refractory LBCL in the salvage setting, lack of outcome durability and toxicity remain. We delineated the relative clinical benefit of the innovative experimental CAR T-cell approaches to Yescarta for insights into the ongoing efforts to address these inadequacies. Tandem CAR T-cells may provide higher efficacy and safer profile than Yescarta. Toxicity attenuated CAR T-cells present remarkable safety but no Progression-Free Survival (PFS) benefit.

### Competing Interest Statement

The authors have declared no competing interest.

### Clinical Protocols

&lt;https://journal.ppcr.org/index.php/ppcrjournal/article/view/142&gt; 

### Funding Statement

This study did not receive any funding

### Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was based on the published data by the eligible clinical trials in this study. Therefore, ethics committee approval or informed consent statement were not required since the study did not involve patients or the public in the design, conduct, reporting, or dissemination plans. 

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Individual patient data obtained from the eligible clinical trials analyzed in this study and any materials generated during the study are available and will be released via a material transfer agreement and study protocol, if available.

&lt;https://journal.ppcr.org/index.php/ppcrjournal/article/view/142&gt; 

*   ASCT
    :   autologous stem cell transplantation
    B-ALL
    :   B-cell acute lymphoblastic leukemia
    BCMA
    :   B-cell maturation antigen
    CAR
    :   chimeric antigen receptor
    CD
    :   cluster of differentiation
    ChiCTR
    :   Chinese clinical trial registry
    CI
    :   confidence interval
    CR
    :   complete response
    CRES
    :   car T cell-related encephalopathy syndrome
    CRR
    :   complete response rate
    CRS
    :   cytokine release syndrome
    CRS
    :   cytokine release syndrome
    DLBCL
    :   diffuse large B-cell lymphoma
    DOR
    :   duration of response
    EFS
    :   event-free survival
    ESS
    :   effective sample size
    HGBCL
    :   high-grade B-cell lymphoma
    HR
    :   hazard ratio
    Hu
    :   human
    IFN-γ
    :   interferon-γ
    IL-2
    :   interleukins-2
    IPD
    :   individual patient data
    KM
    :   Kaplan-Meier
    LBCL
    :   large B-cell lymphoma
    MAIC
    :   matching adjusted indirect comparisons
    NCT
    :   national clinical trial
    NHL
    :   non-Hodgkin lymphoma
    NT
    :   neurotoxicity
    OR
    :   odds ratio
    ORR
    :   objective response rate
    OS
    :   overall survival
    PFS
    :   progression free survival
    PH
    :   proportional hazards
    PPCR
    :   principles and practice of clinical research
    PRISMA
    :   preferred reporting items for systematic reviews and meta-analyses
    R/R LBCL
    :   relapsed/refractory large B-cell lymphoma
    RR
    :   relative risk
    RS
    :   Richter’s transformation
    scFv
    :   single-chain variable fragment
    SD
    :   stable disease
    TNF-α
    :   tumor necrosis factor-α
    trDLBCL
    :   transformed DLBCL
    ZUMA-1
    :   name of Yescarta clinical trial" />
<meta name="og-type" property="og:type" content="article" />
<meta name="og-image" property="og:image" content="" />
<meta name="citation_date" content="2021-10-26" />
<meta name="description" content="medRxiv - The Preprint Server for Health Sciences" />
<meta name="generator" content="Drupal 7 (http://drupal.org)" />
<link rel="canonical" href="https://www.medrxiv.org/content/10.1101/2021.10.24.21265450v1" />
<link rel="shortlink" href="https://www.medrxiv.org/node/426533" />
    <title>Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Rev… | medRxiv</title>  
    <link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__7SC0i-kTgUlQGKuqbmyS18Sez8FDO-aG9FSHkGrLGl8__9Xf-fJpmF9h8tvWywQTaOzJzFLt4sEfx108Wh1gYmm0__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<link type="text/css" rel="stylesheet" href="//cdn.jsdelivr.net/qtip2/2.2.1/jquery.qtip.min.css" media="all" />
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__6CA0-YpwAeHt1tcr6dmX5ZBUuxlddlGnE8FCmWRwxOw__M2jATP9fgS6Hut-L0G3s312CoMA5SDjnuWFM3KPLIRs__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<style type="text/css" media="all">
/* <![CDATA[ */
#sliding-popup.sliding-popup-bottom,#sliding-popup.sliding-popup-bottom .eu-cookie-withdraw-banner,.eu-cookie-withdraw-tab{background:gray}#sliding-popup.sliding-popup-bottom.eu-cookie-withdraw-wrapper{background:transparent}#sliding-popup .popup-content #popup-text h1,#sliding-popup .popup-content #popup-text h2,#sliding-popup .popup-content #popup-text h3,#sliding-popup .popup-content #popup-text p,.eu-cookie-compliance-secondary-button,.eu-cookie-withdraw-tab{color:#fff !important}.eu-cookie-withdraw-tab{border-color:#fff}.eu-cookie-compliance-more-button{color:#fff !important}
/* ]]> */
</style>

<!--[if lte IE 7]>
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__ElJr3PIJEvw3qLXc1cnYiLj2G4KgDPSXFOfm6Phf8hw__JdWGm15cDWjsK6KrFlQVXQix9YgNeYysf22XZHj-Y-c__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<![endif]-->
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__Wnlyen9qEpwh_Qaf9okEu4QdVGM0BDothxeqA6Nbvo8__EJmw6SZD9bYoS8jocCpPYS3JFRURpdzmuvJoAUNiI-g__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__XPg6Aobs217v0T9rA_Y-wMrH3jyqmqunImGwMN4WMEE__Nc8_6i0mjd_g-hzHvpxLmo5g2aluEkJf5SXcEKb7YRY__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />

<!--[if (lt IE 9)&(!IEMobile)]>
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__XH6bpcI0f2dImc-p674DLCZtWBGb-QwxJK1YexVGtno__vUceGprdo5nIhV6DH93X7fI3r8RcTJbChbas9TQXeW4__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<![endif]-->

<!--[if gte IE 9]><!-->
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__2WBMox6sOrN42ss5lCnH7WWVRdFdJCxtTKnQJYRwTE4__yqNvNYLvMpjy3ffuJrjjm9uW2i-Me1c23KLYuWHaqio__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<!--<![endif]-->
<link type="text/css" rel="stylesheet" href="https://www.medrxiv.org/sites/default/files/advagg_css/css__GJ_y0JYBjHihOcdJg-wLEQWRfqvBxU74PCdjUcUHlyY__f0nQteVSjWTKq2ga8E2qYttGognShmPZZJdeGhQoNFI__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.css" media="all" />
<link type="text/css" rel="stylesheet" href="https://d33xdlntwy0kbs.cloudfront.net/cshl_custom_medrxiv.css" media="all" />
    <script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__BKYqkKToQ7EjirB7eIdMEH5521EU3da9IpoOs8Ex2XI__aSjVoX8giBmLhN2EbCgIGQJNu89Mh5aVu1LvI_gkJ7Y__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.js"></script>
<script type="text/javascript" src="//cdn.jsdelivr.net/qtip2/2.2.1/jquery.qtip.min.js"></script>
<script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__4Cn2dxvNlsJ-sHe6QOTLREaQvcqb0Yh0Zm9tTOHtQow__DGggC5UtYkPCwIH8nsa7Vw7hug93fb9QVVl0UJ3mfMM__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.js"></script>
<script type="text/javascript" src="https://www.google.com/recaptcha/api.js?hl=en&amp;render=explicit&amp;onload=drupalRecaptchaOnload"></script>
<script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__dGWpV57YWu3sX6UOe04RMH-iP9jSkEP7Ajt0caYXZZk__sUEhH4BzLc9Xn679uyzc7yvwgMkxjsks2WFVnFK0PiI__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.js"></script>
<script type="text/javascript" async="async" src="https://scholar.google.com/scholar_js/casa.js"></script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
/*!
 * yepnope1.5.4
 * (c) WTFPL, GPLv2
 */
(function(a,b,c){function d(a){return"[object Function]"==o.call(a)}function e(a){return"string"==typeof a}function f(){}function g(a){return!a||"loaded"==a||"complete"==a||"uninitialized"==a}function h(){var a=p.shift();q=1,a?a.t?m(function(){("c"==a.t?B.injectCss:B.injectJs)(a.s,0,a.a,a.x,a.e,1)},0):(a(),h()):q=0}function i(a,c,d,e,f,i,j){function k(b){if(!o&&g(l.readyState)&&(u.r=o=1,!q&&h(),l.onload=l.onreadystatechange=null,b)){"img"!=a&&m(function(){t.removeChild(l)},50);for(var d in y[c])y[c].hasOwnProperty(d)&&y[c][d].onload()}}var j=j||B.errorTimeout,l=b.createElement(a),o=0,r=0,u={t:d,s:c,e:f,a:i,x:j};1===y[c]&&(r=1,y[c]=[]),"object"==a?l.data=c:(l.src=c,l.type=a),l.width=l.height="0",l.onerror=l.onload=l.onreadystatechange=function(){k.call(this,r)},p.splice(e,0,u),"img"!=a&&(r||2===y[c]?(t.insertBefore(l,s?null:n),m(k,j)):y[c].push(l))}function j(a,b,c,d,f){return q=0,b=b||"j",e(a)?i("c"==b?v:u,a,b,this.i++,c,d,f):(p.splice(this.i++,0,a),1==p.length&&h()),this}function k(){var a=B;return a.loader={load:j,i:0},a}var l=b.documentElement,m=a.setTimeout,n=b.getElementsByTagName("script")[0],o={}.toString,p=[],q=0,r="MozAppearance"in l.style,s=r&&!!b.createRange().compareNode,t=s?l:n.parentNode,l=a.opera&&"[object Opera]"==o.call(a.opera),l=!!b.attachEvent&&!l,u=r?"object":l?"script":"img",v=l?"script":u,w=Array.isArray||function(a){return"[object Array]"==o.call(a)},x=[],y={},z={timeout:function(a,b){return b.length&&(a.timeout=b[0]),a}},A,B;B=function(a){function b(a){var a=a.split("!"),b=x.length,c=a.pop(),d=a.length,c={url:c,origUrl:c,prefixes:a},e,f,g;for(f=0;f<d;f++)g=a[f].split("="),(e=z[g.shift()])&&(c=e(c,g));for(f=0;f<b;f++)c=x[f](c);return c}function g(a,e,f,g,h){var i=b(a),j=i.autoCallback;i.url.split(".").pop().split("?").shift(),i.bypass||(e&&(e=d(e)?e:e[a]||e[g]||e[a.split("/").pop().split("?")[0]]),i.instead?i.instead(a,e,f,g,h):(y[i.url]?i.noexec=!0:y[i.url]=1,f.load(i.url,i.forceCSS||!i.forceJS&&"css"==i.url.split(".").pop().split("?").shift()?"c":c,i.noexec,i.attrs,i.timeout),(d(e)||d(j))&&f.load(function(){k(),e&&e(i.origUrl,h,g),j&&j(i.origUrl,h,g),y[i.url]=2})))}function h(a,b){function c(a,c){if(a){if(e(a))c||(j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}),g(a,j,b,0,h);else if(Object(a)===a)for(n in m=function(){var b=0,c;for(c in a)a.hasOwnProperty(c)&&b++;return b}(),a)a.hasOwnProperty(n)&&(!c&&!--m&&(d(j)?j=function(){var a=[].slice.call(arguments);k.apply(this,a),l()}:j[n]=function(a){return function(){var b=[].slice.call(arguments);a&&a.apply(this,b),l()}}(k[n])),g(a[n],j,b,n,h))}else!c&&l()}var h=!!a.test,i=a.load||a.both,j=a.callback||f,k=j,l=a.complete||f,m,n;c(h?a.yep:a.nope,!!i),i&&c(i)}var i,j,l=this.yepnope.loader;if(e(a))g(a,0,l,0);else if(w(a))for(i=0;i<a.length;i++)j=a[i],e(j)?g(j,0,l,0):w(j)?B(j):Object(j)===j&&h(j,l);else Object(a)===a&&h(a,l)},B.addPrefix=function(a,b){z[a]=b},B.addFilter=function(a){x.push(a)},B.errorTimeout=1e4,null==b.readyState&&b.addEventListener&&(b.readyState="loading",b.addEventListener("DOMContentLoaded",A=function(){b.removeEventListener("DOMContentLoaded",A,0),b.readyState="complete"},0)),a.yepnope=k(),a.yepnope.executeStack=h,a.yepnope.injectJs=function(a,c,d,e,i,j){var k=b.createElement("script"),l,o,e=e||B.errorTimeout;k.src=a;for(o in d)k.setAttribute(o,d[o]);c=j?h:c||f,k.onreadystatechange=k.onload=function(){!l&&g(k.readyState)&&(l=1,c(),k.onload=k.onreadystatechange=null)},m(function(){l||(l=1,c(1))},e),i?k.onload():n.parentNode.insertBefore(k,n)},a.yepnope.injectCss=function(a,c,d,e,g,i){var e=b.createElement("link"),j,c=i?h:c||f;e.href=a,e.rel="stylesheet",e.type="text/css";for(j in d)e.setAttribute(j,d[j]);g||(n.parentNode.insertBefore(e,n),m(c,0))}})(this,document);

//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
yepnope({
  test: Modernizr.matchmedia,
  nope: '/sites/all/libraries/media-match/media.match.min.js'
});
//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
var _prum=[['id', '52e95df3abe53d2e33000000'], ['mark', 'firstbyte',
      (new Date()).getTime()]]; (function() {
      var s=document.getElementsByTagName('script')[0],
      p=document.createElement('script');
      p.async='async'; p.src='//rum-static.pingdom.net/prum.min.js';s.parentNode.insertBefore(p,s);})();
//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
if(typeof window.MathJax === "undefined") window.MathJax = { menuSettings: { zoom: "Click" } };
//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
(function(i,s,o,g,r,a,m){i["GoogleAnalyticsObject"]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,"script","//www.google-analytics.com/analytics.js","ga");ga("create", "UA-141606356-1", {"cookieDomain":"auto"});ga("set", "page", location.pathname + location.search + location.hash);ga("send", "pageview");ga('create', 'UA-189672-38', 'auto', {'name': 'hwTracker'});
ga('set', 'anonymizeIp', true);
ga('hwTracker.send', 'pageview');
//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
jQuery.extend(Drupal.settings,{"basePath":"\/","pathPrefix":"","ajaxPageState":{"theme":"jcore_1","theme_token":"NeODB3_1bQpB0ZKc0tUXSdXibfT__pD5CXo1JFRHPck"},"colorbox":{"opacity":"0.85","current":"{current} of {total}","previous":"\u00ab Prev","next":"Next \u00bb","close":"Close","maxWidth":"98%","maxHeight":"98%","fixed":true,"mobiledetect":true,"mobiledevicewidth":"480px"},"highwire":{"nid":"426533","apath":"\/medrxiv\/early\/2021\/10\/26\/2021.10.24.21265450.atom","pisa":"medrxiv;2021.10.24.21265450v1","ac":{"\/medrxiv\/early\/2021\/10\/26\/2021.10.24.21265450.atom":{"access":{"full":true},"pisa_id":"","apath":"\/medrxiv\/early\/2021\/10\/26\/2021.10.24.21265450.atom","jcode":"medrxiv"}},"processed":["highwire_math"],"markup":[{"requested":"abstract","variant":"abstract","view":"abstract","pisa":"medrxiv;2021.10.24.21265450v1"}],"modal_window_width":"560","share_modal_width":"560","share_modal_title":"Share this Article"},"jcarousel":{"ajaxPath":"\/jcarousel\/ajax\/views"},"instances":"{\u0022highwire_abstract_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:20,\u0022height\u0022:20,\u0022border\u0022:1,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-abstract-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022right center\u0022,\u0022my\u0022:\u0022left center\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022shift\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter click \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}},\u0022highwire_author_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:15,\u0022height\u0022:15,\u0022border\u0022:1,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-author-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022top center\u0022,\u0022my\u0022:\u0022bottom center\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}},\u0022highwire_reflinks_tooltip\u0022:{\u0022content\u0022:{\u0022text\u0022:\u0022\u0022},\u0022style\u0022:{\u0022tip\u0022:{\u0022width\u0022:15,\u0022height\u0022:15,\u0022border\u0022:1,\u0022mimic\u0022:\u0022top center\u0022,\u0022offset\u0022:0,\u0022corner\u0022:true},\u0022classes\u0022:\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\u0022,\u0022classes_custom\u0022:\u0022hw-tooltip hw-ref-link-tooltip\u0022},\u0022position\u0022:{\u0022at\u0022:\u0022bottom left\u0022,\u0022my\u0022:\u0022top left\u0022,\u0022viewport\u0022:true,\u0022adjust\u0022:{\u0022method\u0022:\u0022flip\u0022}},\u0022show\u0022:{\u0022event\u0022:\u0022mouseenter \u0022,\u0022solo\u0022:true},\u0022hide\u0022:{\u0022event\u0022:\u0022mouseleave \u0022,\u0022fixed\u0022:1,\u0022delay\u0022:\u0022100\u0022}}}","qtipDebug":"{\u0022leaveElement\u0022:0}","panel_ajax_tab":{"path":"sites\/all\/modules\/contrib\/panels_ajax_tab"},"disqus":{"domain":"medRxiv","url":"https:\/\/www.medrxiv.org\/content\/10.1101\/2021.10.24.21265450v1","title":"Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed\/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Rev\u2026","identifier":"node\/426533"},"panels_ajax_pane":{"new-41":"{\u0022encrypted\u0022:\u0022{\\\u0022encrypted\\\u0022:\\\u00227NGZ4yimWpEO14mgxBHjoU\\\\\\\/oMUl7oeezeKtsCrw+MrveQkh897Dkxrhw+Xj2K5yt9Ybxug43iMIEXTRXDRtqKCeqm3wX2DuVgE78jY3MTkaPGkAiGfVfQwz3WlAF\\\\\\\/m73A4JhJ5nA2Fu15NPWoyNkmODAV78XBr+e351r86A6Z43HZL9F4n+Vx33eCiJlLbKnKJV53gLO\\\\\\\/MHefx8NmtdjJano4TNLWg7Yt\\\\\\\/x7tGyqrbRdgBmqlV9KhkZOpnysKZUDgs\\\\\\\/x\\\\\\\/E4GEgUJKQ9NgYDTO7JYTHqV+D1EojKPrn2EbPOx4FQlY4MV2bBUm97PscH5ZTTG9cto0iLWaglhI+IaT9eB44WeAcS8RaMoePphlp\\\\\\\/MybEBaSrVfwzIMIqUS+KSizsv3hkooNjkjY\\\\\\\/s7utEGrZtOtx1XM+1OBpC8tRVWW\\\\\\\/LWCPHHjvciBBMYZRQzeeLd0MoH2YDrwkLd5xzNq6W0m1FtfOJrgTpcDdkuCLR74D2qhVBMyKEGdMLtAh50zooiUfF6CDNLby76GG8fAqlMQyB0ru\\\\\\\/EN13dOX6G6TJ5UtpdR2Ksu+Kk\\\\\\\/3SN62rNrE0qU6TGJMai39Zwo\\\\\\\/T8QeoU1AuRm\\\\\\\/cpiguWtqEO09vbrSzEXNlWodLaUuNidHHqJDaN1RGklVuFhIpLHdNujDm5TzPyMJ48IEX3N4atuhXWfMGqDco4GJYb2lj\\\\\\\/834+gzl0mNOPIvB1QNEXlbh8Psn1vcRXKp4un\\\\\\\/\\\\\\\/jSUCThrW7RCf1yzhXMioTtyhJneCFfjOd1eyqXuxduneEI3qlr1XUpKYTnP9fd3mOfARgB4st\\\\\\\/S\\\\\\\/99LPtpCBKrsITQNGNwkbHSeCQAUcgosCoC2WtZ+XmfpbijJ+CrJlgOAxNq\\\\\\\/iCq9UIXJQ3311EJB1dcp+joAv1Mx5IwSTGsltUFSSelHjZTl671HQ77VIPn9Xr120EdhPHEndi3OwKqQp0gR0lcEmt54pWrJM1gIV0e7yMX8pFGFq10g+vcmN3ehRhl0WPMu9q6+bVYzHXqnyKsBe\\\\\\\/BuvmJo4RbdadEmeooPVkuAePvfYGN9QV5LTvYO2SPjX9WvVqWaxYboqTDbMe00N8KDnwL2vNeTIN8aXjQiik81NgZVptQOjN9lWhFasxyKmmOXxNE1a\\\\\\\/fE0E3FbfimMk81iqZfwR0H9nBT1gf0orzrveHIiLMHA3kbCWayDJxh4d4lcvutKhiSr+sIvJtSLXPNvOHw+Z7yMtOU3J\\\\\\\/7va6n\\\\\\\/hXV40Xgo\\\\\\\/MAlNDKGIH2o1PrBk1XbgdxeAu6U1HYKLZbQ\\\u0022,\\\u0022iv\\\u0022:\\\u0022f0rvWJS9hXPzgr2HuvA3gA==\\\u0022,\\\u0022salt\\\u0022:\\\u0022f9d8845712f72c9fee5db7d9ff111eab\\\u0022}\u0022,\u0022hmac\u0022:\u0022a78a3c760ebdbe8078b07f72231adc8a74a7e017532570cda024d2705a6fe10d\u0022}"},"urlIsAjaxTrusted":{"\/content\/10.1101\/2021.10.24.21265450v1":true},"ws_fl":{"width":100,"height":21},"ws_gpo":{"size":"","annotation":"","lang":"","callback":"","width":300},"color":{"logo":"https:\/\/www.medrxiv.org\/sites\/default\/files\/medrxiv_internal_logo.png"},"highwire_list_expand":{"is_collapsed":"1"},"highwireResponsive":{"enquire_enabled":1,"breakpoints_configured":1,"breakpoints":{"zero":"all and (min-width: 0px)","xsmall":"all and (min-width: 380px)","narrow":"all and (min-width: 768px) and (min-device-width: 768px), (max-device-width: 800px) and (min-width: 768px) and (orientation:landscape)","normal":"all and (min-width: 980px) and (min-device-width: 980px), all and (max-device-width: 1024px) and (min-width: 1024px) and (orientation:landscape)","wide":"all and (min-width: 1220px)"}},"eu_cookie_compliance":{"popup_enabled":1,"popup_agreed_enabled":0,"popup_hide_agreed":0,"popup_clicking_confirmation":1,"popup_scrolling_confirmation":false,"popup_html_info":"\u003Cdiv\u003E\n  \u003Cdiv class =\u0022popup-content info\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n      \u003Cp\u003EWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.\u003C\/p\u003E\n    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022agree-button eu-cookie-compliance-default-button\u0022\u003EContinue\u003C\/button\u003E\n                    \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button\u0022\u003EFind out more\u003C\/button\u003E\n          \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E","use_mobile_message":false,"mobile_popup_html_info":"\u003Cdiv\u003E\n  \u003Cdiv class =\u0022popup-content info\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n          \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022agree-button eu-cookie-compliance-default-button\u0022\u003EContinue\u003C\/button\u003E\n                    \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button\u0022\u003EFind out more\u003C\/button\u003E\n          \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n","mobile_breakpoint":"768","popup_html_agreed":"\u003Cdiv\u003E\n  \u003Cdiv class=\u0022popup-content agreed\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n      \u003Ch2\u003EThank you for accepting cookies\u003C\/h2\u003E\u003Cp\u003EYou can now hide this message or find out more about cookies.\u003C\/p\u003E    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022hide-popup-button eu-cookie-compliance-hide-button\u0022\u003EHide\u003C\/button\u003E\n              \u003Cbutton type=\u0022button\u0022 class=\u0022find-more-button eu-cookie-compliance-more-button-thank-you\u0022 \u003EMore info\u003C\/button\u003E\n          \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E","popup_use_bare_css":false,"popup_height":"auto","popup_width":"100%","popup_delay":1000,"popup_link":"\/help\/cookie-policy","popup_link_new_window":1,"popup_position":null,"popup_language":"en","store_consent":false,"better_support_for_screen_readers":0,"reload_page":0,"domain":"","popup_eu_only_js":0,"cookie_lifetime":"365","cookie_session":false,"disagree_do_not_show_popup":0,"method":"default","whitelisted_cookies":"","withdraw_markup":"\u003Cbutton type=\u0022button\u0022 class=\u0022eu-cookie-withdraw-tab\u0022\u003EPrivacy settings\u003C\/button\u003E\n\u003Cdiv class=\u0022eu-cookie-withdraw-banner\u0022\u003E\n  \u003Cdiv class=\u0022popup-content info\u0022\u003E\n    \u003Cdiv id=\u0022popup-text\u0022\u003E\n      \u003Cp\u003E\u0026lt;h2\u0026gt;We use cookies on this site to enhance your user experience\u0026lt;\/h2\u0026gt;\u0026lt;p\u0026gt;You have given your consent for us to set cookies.\u0026lt;\/p\u0026gt;\u003C\/p\u003E\n    \u003C\/div\u003E\n    \u003Cdiv id=\u0022popup-buttons\u0022\u003E\n      \u003Cbutton type=\u0022button\u0022 class=\u0022eu-cookie-withdraw-button\u0022\u003EWithdraw consent\u003C\/button\u003E\n    \u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n","withdraw_enabled":false},"googleanalytics":{"trackOutbound":1,"trackMailto":1,"trackDownload":1,"trackDownloadExtensions":"7z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip","trackColorbox":1,"trackUrlFragments":1},"jnl_biorxiv_styles":{"defaultJCode":"medrxiv"},"omega":{"layouts":{"primary":"normal","order":["narrow","normal","wide"],"queries":{"narrow":"all and (min-width: 768px) and (min-device-width: 768px), (max-device-width: 800px) and (min-width: 768px) and (orientation:landscape)","normal":"all and (min-width: 980px) and (min-device-width: 980px), all and (max-device-width: 1024px) and (min-width: 1024px) and (orientation:landscape)","wide":"all and (min-width: 1220px)"}}}});
//--><!]]>
</script>
    <!--[if lt IE 9]><script src="http://html5shiv.googlecode.com/svn/trunk/html5.js"></script><![endif]-->
  </head>
  <body class="html not-front not-logged-in page-node page-node- page-node-426533 node-type-highwire-article context-content hw-default-jcode-medrxiv hw-article-type-article">
<!-- Google Tag Manager -->
<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-P4HH5NV" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<script type="text/javascript">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0];var j=d.createElement(s);var dl=l!='dataLayer'?'&l='+l:'';j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;j.type='text/javascript';j.async=true;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-P4HH5NV');</script>
<!-- End Google Tag Manager -->
    <div id="skip-link">
      <a href="#main-content" class="element-invisible element-focusable">Skip to main content</a>
    </div>
        <div class="page clearfix page-box-shadows footer-borders panels-page panels-layout-jcore_2col" id="page">
      <header id="section-header" class="section section-header">
    
  <div id="zone-branding" class="zone zone-branding clearfix print-display-block container-30">
    <div class="grid-15 prefix-1 region region-branding print-display-block" id="region-branding">
  <div class="region-inner region-branding-inner">
        <div class="branding-data clearfix">
            <div class="logo-img">
        <a href="/" rel="home" class="" data-icon-position="" data-hide-link-title="0"><img alt="medRxiv" src="https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png" /></a>      </div>
                </div>
          </div>
</div><div class="grid-11 suffix-1 region region-branding-second print-hidden" id="region-branding-second">
  <div class="region-inner region-branding-second-inner">
    <div class="block block-system block-menu block-main-menu block-system-main-menu odd block-without-title" id="block-system-main-menu">
  <div class="block-inner clearfix">
                
    <div class="content clearfix">
      <nav class="menubar-nav"><ul class="menu" role="menu"><li class="first leaf" role="menuitem"><a href="/" title="" class="" data-icon-position="" data-hide-link-title="0">Home</a></li>
<li class="leaf" role="menuitem"><a href="/content/about-medrxiv" class="" data-icon-position="" data-hide-link-title="0">About</a></li>
<li class="leaf" role="menuitem"><a href="/submit-a-manuscript" class="" data-icon-position="" data-hide-link-title="0">Submit</a></li>
<li class="last leaf" role="menuitem"><a href="/content/alertsrss" title="" class="" data-icon-position="" data-hide-link-title="0">ALERTS / RSS</a></li>
</ul></nav>    </div>
  </div>
</div><div class="block block-panels-mini block-biorxiv-search-box block-panels-mini-biorxiv-search-box even block-without-title" id="block-panels-mini-biorxiv-search-box">
  <div class="block-inner clearfix">
                
    <div class="content clearfix">
      <div class="panel-display panel-1col clearfix" id="mini-panel-biorxiv_search_box">
  <div class="panel-panel panel-col">
    <div><div class="panel-pane pane-highwire-seach-quicksearch" >
  
      
  
  <div class="pane-content">
    <form class="highwire-quicksearch button-style-mini button-style-mini" action="/content/10.1101/2021.10.24.21265450v1" method="post" id="highwire-search-quicksearch-form-0" accept-charset="UTF-8"><div><div class="form-item form-item-label-invisible form-type-textfield form-item-keywords">
  <label class="element-invisible" for="edit-keywords">Search for this keyword </label>
 <input placeholder="Search" type="text" id="edit-keywords" name="keywords" value="" size="60" maxlength="128" class="form-text" />
</div>
<div class="button-wrapper button-mini"><span class="icon-search"></span><input data-icon-only="1" data-font-icon="icon-search" data-icon-position="after" type="submit" id="edit-submit--2" name="op" value="Search" class="form-submit" /></div><input type="hidden" name="form_build_id" value="form-4EUNNFlJHHffwIk7DA6lqw5HWEUQabz_cMFkWp3KBAI" />
<input type="hidden" name="form_id" value="highwire_search_quicksearch_form_0" />
</div></form>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-custom pane-2 advanced-search-link" >
  
      
  
  <div class="pane-content">
    <a href="/search">Advanced Search</a>  </div>

  
  </div>
</div>
  </div>
</div>
    </div>
  </div>
</div>  </div>
</div>  </div>
  
  <div id="zone-header" class="zone zone-header clearfix container-30">
  	      </div>
</header>    
      <section id="section-content" class="section section-content">
    
  <div id="zone-content" class="zone zone-content clearfix container-30">    
        
    <div class="grid-28 suffix-1 prefix-1 region region-content" id="region-content">
  <div class="region-inner region-content-inner">
    <a id="main-content"></a>
                        <div class="block block-system block-main block-system-main odd block-without-title" id="block-system-main">
  <div class="block-inner clearfix">
                
    <div class="content clearfix">
      <div class="panel-display panels-960-layout jcore-2col-layout" >
	  
  <div class="panel-row-wrapper clearfix">
		
		<div class="main-content-wrapper grid-17 suffix-1 alpha">
			<div class="panel-panel panel-region-content">
			  <div class="inside"><div class="panel-pane pane-highwire-article-citation" >
  
      
  
  <div class="pane-content">
    <div class="highwire-article-citation highwire-citation-type-highwire-article node426533" data-node-nid="426533" id="node426533--2653657638" data-pisa="medrxiv;2021.10.24.21265450v1" data-pisa-master="medrxiv;2021.10.24.21265450" data-apath="/medrxiv/early/2021/10/26/2021.10.24.21265450.atom" data-hw-author-tooltip-instance=""><div  class="highwire-cite highwire-cite-highwire-article highwire-citation-medrxiv-article-top clearfix has-author-tooltip" >

  
      <h1 class="highwire-cite-title" id="page-title">Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review</h1>  
      <div  class="highwire-cite-authors" ><span  class="highwire-citation-authors"><span class="highwire-citation-author first hw-author-orcid-logo-wrapper" data-delta="0"><a href="http://orcid.org/0000-0001-9572-7349" target="_blank" class="hw-author-orcid-logo link-icon-only link-icon"><span class="hw-icon-orcid hw-icon-color-orcid"></span> <span class="title element-invisible">View ORCID Profile</span></a><span class="nlm-given-names">Bayarmagnai</span> <span class="nlm-surname">Weinstein</span></span>, <span class="highwire-citation-author" data-delta="1"><span class="nlm-given-names">Bogdan</span> <span class="nlm-surname">Muresan</span></span>, <span class="highwire-citation-author" data-delta="2"><span class="nlm-given-names">Sara</span> <span class="nlm-surname">Solano</span></span>, <span class="highwire-citation-author" data-delta="3"><span class="nlm-given-names">Antonio Vaz</span> <span class="nlm-surname">de Macedo</span></span>, <span class="highwire-citation-author" data-delta="4"><span class="nlm-given-names">YoonJung</span> <span class="nlm-surname">Lee</span></span>, <span class="highwire-citation-author" data-delta="5"><span class="nlm-given-names">Yu-Chen</span> <span class="nlm-surname">Su</span></span>, <span class="highwire-citation-author" data-delta="6"><span class="nlm-given-names">Yeseul</span> <span class="nlm-surname">Ahn</span></span>, <span class="highwire-citation-author" data-delta="7"><span class="nlm-given-names">Gabriela</span> <span class="nlm-surname">Henriquez</span></span>, <span class="highwire-citation-author" data-delta="8"><span class="nlm-given-names">Cristina</span> <span class="nlm-surname">Camargo</span></span>, <span class="highwire-citation-author" data-delta="9"><span class="nlm-given-names">Gwang-Jin</span> <span class="nlm-surname">Kim</span></span>, <span class="highwire-citation-author" data-delta="10"><span class="nlm-given-names">David O.</span> <span class="nlm-surname">Carpenter</span></span></span></div>
  
      <div  class="highwire-cite-metadata" ><span  class="highwire-cite-metadata-doi highwire-cite-metadata"><span class="label">doi:</span> https://doi.org/10.1101/2021.10.24.21265450 </span></div>
  
  
  
</div>
<div id="hw-article-author-popups-node426533--2653657638" style="display: none;"><div class="author-tooltip-0"><div class="author-tooltip-name">Bayarmagnai Weinstein </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span><span class='nlm-institution'>Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health</span>, Boston, MA 02115, <span class='nlm-country'>USA</span></div><div class='author-affiliation'><span class='nlm-sup'>2</span><span class='nlm-institution'>Department of Environmental Health Sciences, School of Public Health, University at Albany</span>, Rensselaer, NY 12144, <span class='nlm-country'>USA</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Bayarmagnai%2BWeinstein%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Weinstein%20B&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link"><a href="/search/author1%3ABayarmagnai%2BWeinstein%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li><li class="author-orcid-link"><a href="http://orcid.org/0000-0001-9572-7349" target="_blank" class="" data-icon-position="" data-hide-link-title="0">ORCID record for Bayarmagnai Weinstein</a></li><li class="author-corresp-email-link last"><span>For correspondence: 
<a href="mailto:bmunkhjargal@albany.edu" class="" data-icon-position="" data-hide-link-title="0">bmunkhjargal@albany.edu</a></span></li></ul></div><div class="author-tooltip-1"><div class="author-tooltip-name">Bogdan Muresan </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>3</span><span class='nlm-institution'>Health Sciences Unit, University of Groningen, University Medical Center Groningen</span>, Groningen, <span class='nlm-country'>The Netherlands</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Bogdan%2BMuresan%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Muresan%20B&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ABogdan%2BMuresan%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-2"><div class="author-tooltip-name">Sara Solano </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span><span class='nlm-institution'>Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health</span>, Boston, MA 02115, <span class='nlm-country'>USA</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Sara%2BSolano%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Solano%20S&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ASara%2BSolano%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-3"><div class="author-tooltip-name">Antonio Vaz de Macedo </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span><span class='nlm-institution'>Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health</span>, Boston, MA 02115, <span class='nlm-country'>USA</span></div><div class='author-affiliation'><span class='nlm-sup'>4</span><span class='nlm-institution'>Hematology Clinic, Hospital da Polícia Militar</span>, Belo Horizonte, MG, CEP 30110-013, <span class='nlm-country'>Brazil</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Antonio%2BVaz%2Bde%2BMacedo%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=de%20Macedo%20AV&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AAntonio%2BVaz%2Bde%2BMacedo%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-4"><div class="author-tooltip-name">YoonJung Lee </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>5</span><span class='nlm-institution'>Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center</span>, Amarillo, TX 79106, <span class='nlm-country'>USA</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=YoonJung%2BLee%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Lee%20Y&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AYoonJung%2BLee%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-5"><div class="author-tooltip-name">Yu-Chen Su </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>6</span><span class='nlm-institution'>Inari Medical, Biostatistics and Programming Dept</span>, Irvine, CA 92618, <span class='nlm-country'>USA</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Yu-Chen%2BSu%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Su%20Y&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AYu-Chen%2BSu%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-6"><div class="author-tooltip-name">Yeseul Ahn </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>5</span><span class='nlm-institution'>Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center</span>, Amarillo, TX 79106, <span class='nlm-country'>USA</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Yeseul%2BAhn%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Ahn%20Y&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AYeseul%2BAhn%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-7"><div class="author-tooltip-name">Gabriela Henriquez </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>1</span><span class='nlm-institution'>Principles and Practice of Clinical Research (PPCR) Program, ECPE, Harvard T.H. Chan School of Public Health</span>, Boston, MA 02115, <span class='nlm-country'>USA</span></div><div class='author-affiliation'><span class='nlm-sup'>7</span><span class='nlm-institution'>Iberoamerican University</span>, Santo Domingo 10203, <span class='nlm-country'>Dominican Republic</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Gabriela%2BHenriquez%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Henriquez%20G&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AGabriela%2BHenriquez%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-8"><div class="author-tooltip-name">Cristina Camargo </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>8</span><span class='nlm-institution'>School of Medicine, Univesida de São Paulo</span>, Brazil CEP 01246903</div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Cristina%2BCamargo%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Camargo%20C&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ACristina%2BCamargo%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-9"><div class="author-tooltip-name">Gwang-Jin Kim </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>9</span><span class='nlm-institution'>Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg</span>, 79104 Freiburg, <span class='nlm-country'>Germany</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=Gwang-Jin%2BKim%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Kim%20G&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3AGwang-Jin%2BKim%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div><div class="author-tooltip-10"><div class="author-tooltip-name">David O. Carpenter </div><div class="author-tooltip-affiliation"><span class="author-tooltip-text"><div class='author-affiliation'><span class='nlm-sup'>2</span><span class='nlm-institution'>Department of Environmental Health Sciences, School of Public Health, University at Albany</span>, Rensselaer, NY 12144, <span class='nlm-country'>USA</span></div><div class='author-affiliation'><span class='nlm-sup'>10</span><span class='nlm-institution'>Institute for Health and the Environment, University at Albany</span>, Rensselaer, NY 12144, <span class='nlm-country'>USA</span></div></span></div><ul class="author-tooltip-find-more"><li class="author-tooltip-gs-link first"><a href="/lookup/google-scholar?link_type=googlescholar&amp;gs_type=author&amp;author%5B0%5D=David%2BO.%2BCarpenter%2B" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on Google Scholar</a></li><li class="author-tooltip-pubmed-link"><a href="/lookup/external-ref?access_num=Carpenter%20DO&amp;link_type=AUTHORSEARCH" target="_blank" class="" data-icon-position="" data-hide-link-title="0">Find this author on PubMed</a></li><li class="author-site-search-link last"><a href="/search/author1%3ADavid%2BO.%2BCarpenter%2B" rel="nofollow" class="" data-icon-position="" data-hide-link-title="0">Search for this author on this site</a></li></ul></div></div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-panel-tabs pane-panels-ajax-tab-tabs" >
  
      
  
  <div class="pane-content">
    <div class="item-list"><ul class="tabs inline panels-ajax-tab"><li class="first"><a href="/content/10.1101/2021.10.24.21265450v1" class="panels-ajax-tab-tab" data-panel-name="biorxiv_tab_art" data-target-id="highwire_article_tabs" data-entity-context="node:426533" data-trigger="" data-url-enabled="1">Abstract</a><a href="/panels_ajax_tab/biorxiv_tab_art/node:426533/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/10.1101/2021.10.24.21265450v1.full-text" class="panels-ajax-tab-tab" data-panel-name="article_tab_full_text" data-target-id="highwire_article_tabs" data-entity-context="node:426533" data-trigger="full-text" data-url-enabled="1">Full Text</a><a href="/panels_ajax_tab/article_tab_full_text/node:426533/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/10.1101/2021.10.24.21265450v1.article-info" class="panels-ajax-tab-tab" data-panel-name="biorxiv_tab_info" data-target-id="highwire_article_tabs" data-entity-context="node:426533" data-trigger="article-info" data-url-enabled="1">Info/History</a><a href="/panels_ajax_tab/biorxiv_tab_info/node:426533/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/10.1101/2021.10.24.21265450v1.article-metrics" class="panels-ajax-tab-tab" data-panel-name="article_tab_metrics" data-target-id="highwire_article_tabs" data-entity-context="node:426533" data-trigger="article-metrics" data-url-enabled="1">Metrics</a><a href="/panels_ajax_tab/article_tab_metrics/node:426533/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/10.1101/2021.10.24.21265450v1.supplementary-material" class="panels-ajax-tab-tab" data-panel-name="biorxiv_tab_data" data-target-id="highwire_article_tabs" data-entity-context="node:426533" data-trigger="supplementary-material" data-url-enabled="1">Supplementary material</a><a href="/panels_ajax_tab/biorxiv_tab_data/node:426533/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li><a href="/content/10.1101/2021.10.24.21265450v1.external-links" class="panels-ajax-tab-tab" data-panel-name="article_tab_data_code" data-target-id="highwire_article_tabs" data-entity-context="node:426533" data-trigger="external-links" data-url-enabled="1">Data/Code</a><a href="/panels_ajax_tab/article_tab_data_code/node:426533/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li><li class="last"><a href="/content/10.1101/2021.10.24.21265450v1.full.pdf+html" class="panels-ajax-tab-tab" data-panel-name="biorxiv_tab_pdf" data-target-id="highwire_article_tabs" data-entity-context="node:426533" data-trigger="full.pdf+html" data-url-enabled="1"><i class="icon-file-alt"></i> Preview PDF</a><a href="/panels_ajax_tab/biorxiv_tab_pdf/node:426533/1" rel="nofollow" style="display:none" class="js-crawler-link"></a></li></ul></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-panel-tabs-container" >
  
      
  
  <div class="pane-content">
    <div data-panels-ajax-tab-preloaded="biorxiv_tab_art" id="panels-ajax-tab-container-highwire_article_tabs" class="panels-ajax-tab-container"><div class="panels-ajax-tab-loading" style ="display:none"><img class="loading" src="https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif" alt="Loading" title="Loading" /></div><div class="panels-ajax-tab-wrap-biorxiv_tab_art"><div class="panel-display panel-1col clearfix" >
  <div class="panel-panel panel-col">
    <div><div class="panel-pane pane-highwire-markup" >
  
      
  
  <div class="pane-content">
    <div class="highwire-markup"><div xmlns="http://www.w3.org/1999/xhtml" data-highwire-cite-ref-tooltip-instance="highwire_reflinks_tooltip" class="content-block-markup" xmlns:xhtml="http://www.w3.org/1999/xhtml"><div class="article abstract-view "><span class="highwire-journal-article-marker-start"></span><div class="section abstract" id="abstract-1"><h2 class="">ABSTRACT</h2><p id="p-3">Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the currently approved CAR T-cell therapies. In the absence of head-to-head comparisons and randomized controlled trials, we performed Matching Adjusted Indirect Comparisons to quantify the relative efficacy and safety of experimental CARs against Axicabtagene ciloleucel (Yescarta), the first FDA-approved CAR. A total of 182 R/R LBCL patients from 15 clinical trials with individual patient data (IPD) were pooled into eight populations by their CAR T-cell constructs and +/-ASCT status. The study endpoints were Progression-Free Survival (PFS), grade ≥ 3 cytokine release syndrome (CRS), and grade ≥ 3 neurotoxicity (NT). Tandem CD19.CD20.4-1BBζ CARs indicated favorable ef?cacy and safety, whereas the co-infusion of CD19 &amp; CD20 with 4-1BBζ showed no clinical benefit compared to Yescarta. Third generation CD19. CD28. 4-1BBζ, and sequential administration of autologous stem cell transplantation (ASCT) and CD19. CARs presented statistically insignificant yet improved PFS and safety except for ASCT combined intervention which had suggestively higher NT risk than Yescarta. CARs with modified co-stimulatory domains to reduce toxicity (Hu19. CD8.28Zζ and CD19. BBz.86ζ) presented remarkable safety with no severe adverse events; however, both presented worse PFS than Yescarta. Third-generation CARs demonstrated statistically significantly lower NT than Yescarta. CD20. 4-1BBζ data suggested targeting CD20 antigen alone lacks clinical or safety benefit compared to Yescarta. Further comparisons with other FDA-approved CARs are needed.</p><div id="sec-1" class="subsection"><p id="p-4"><strong>NOVELTY AND IMPACT</strong> Although currently approved CAR T-cells demonstrated unprecedently high response in relapsed / refractory LBCL in the salvage setting, lack of outcome durability and toxicity remain. We delineated the relative clinical benefit of the innovative experimental CAR T-cell approaches to Yescarta for insights into the ongoing efforts to address these inadequacies. Tandem CAR T-cells may provide higher efficacy and safer profile than Yescarta. Toxicity attenuated CAR T-cells present remarkable safety but no Progression-Free Survival (PFS) benefit.</p></div></div><h3>Competing Interest Statement</h3><p id="p-5">The authors have declared no competing interest.</p><h3>Clinical Protocols</h3><p id="p-6">
<a href="https://journal.ppcr.org/index.php/ppcrjournal/article/view/142">https://journal.ppcr.org/index.php/ppcrjournal/article/view/142</a>
</p><h3>Funding Statement</h3><p id="p-7">This study did not receive any funding</p><h3>Author Declarations</h3><p id="p-8">I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p id="p-9">Yes</p><p id="p-10">The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p id="p-11">This study was based on the published data by the eligible clinical trials in this study. Therefore, ethics committee approval or informed consent statement were not required since the study did not involve patients or the public in the design, conduct, reporting, or dissemination plans.
</p><p id="p-12">I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.</p><p id="p-13">Yes</p><p id="p-14">I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p id="p-15">Yes</p><p id="p-16"> I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p id="p-17">Yes</p><div class="section data-availability" id="sec-28"><h2 class="">Data Availability</h2><p id="p-65">Individual patient data obtained from the eligible clinical trials analyzed in this study and any materials generated during the study are available and will be released via a material transfer agreement and study protocol, if available.</p><p id="p-66">
<a href="https://journal.ppcr.org/index.php/ppcrjournal/article/view/142">https://journal.ppcr.org/index.php/ppcrjournal/article/view/142</a>
</p></div><div class="section glossary"><li class="fn" id="glossary-1"><h2 class="">ABBREVIATIONS</h2><dl id="def-list-1"><dt id="def-item-1">ASCT<span class="def-item-dt-sep"></span></dt><dd>autologous stem cell transplantation<span class="def-item-dd-sep"></span></dd><dt id="def-item-2">B-ALL<span class="def-item-dt-sep"></span></dt><dd>B-cell acute lymphoblastic leukemia<span class="def-item-dd-sep"></span></dd><dt id="def-item-3">BCMA<span class="def-item-dt-sep"></span></dt><dd>B-cell maturation antigen<span class="def-item-dd-sep"></span></dd><dt id="def-item-4">CAR<span class="def-item-dt-sep"></span></dt><dd>chimeric antigen receptor<span class="def-item-dd-sep"></span></dd><dt id="def-item-5">CD<span class="def-item-dt-sep"></span></dt><dd>cluster of differentiation<span class="def-item-dd-sep"></span></dd><dt id="def-item-6">ChiCTR<span class="def-item-dt-sep"></span></dt><dd>Chinese clinical trial registry<span class="def-item-dd-sep"></span></dd><dt id="def-item-7">CI<span class="def-item-dt-sep"></span></dt><dd>confidence interval<span class="def-item-dd-sep"></span></dd><dt id="def-item-8">CR<span class="def-item-dt-sep"></span></dt><dd>complete response<span class="def-item-dd-sep"></span></dd><dt id="def-item-9">CRES<span class="def-item-dt-sep"></span></dt><dd>car T cell-related encephalopathy syndrome<span class="def-item-dd-sep"></span></dd><dt id="def-item-10">CRR<span class="def-item-dt-sep"></span></dt><dd>complete response rate<span class="def-item-dd-sep"></span></dd><dt id="def-item-11">CRS<span class="def-item-dt-sep"></span></dt><dd>cytokine release syndrome<span class="def-item-dd-sep"></span></dd><dt id="def-item-12">CRS<span class="def-item-dt-sep"></span></dt><dd>cytokine release syndrome<span class="def-item-dd-sep"></span></dd><dt id="def-item-13">DLBCL<span class="def-item-dt-sep"></span></dt><dd>diffuse large B-cell lymphoma<span class="def-item-dd-sep"></span></dd><dt id="def-item-14">DOR<span class="def-item-dt-sep"></span></dt><dd>duration of response<span class="def-item-dd-sep"></span></dd><dt id="def-item-15">EFS<span class="def-item-dt-sep"></span></dt><dd>event-free survival<span class="def-item-dd-sep"></span></dd><dt id="def-item-16">ESS<span class="def-item-dt-sep"></span></dt><dd>effective sample size<span class="def-item-dd-sep"></span></dd><dt id="def-item-17">HGBCL<span class="def-item-dt-sep"></span></dt><dd>high-grade B-cell lymphoma<span class="def-item-dd-sep"></span></dd><dt id="def-item-18">HR<span class="def-item-dt-sep"></span></dt><dd>hazard ratio<span class="def-item-dd-sep"></span></dd><dt id="def-item-19">Hu<span class="def-item-dt-sep"></span></dt><dd>human<span class="def-item-dd-sep"></span></dd><dt id="def-item-20">IFN-γ<span class="def-item-dt-sep"></span></dt><dd>interferon-γ<span class="def-item-dd-sep"></span></dd><dt id="def-item-21">IL-2<span class="def-item-dt-sep"></span></dt><dd>interleukins-2<span class="def-item-dd-sep"></span></dd><dt id="def-item-22">IPD<span class="def-item-dt-sep"></span></dt><dd>individual patient data<span class="def-item-dd-sep"></span></dd><dt id="def-item-23">KM<span class="def-item-dt-sep"></span></dt><dd>Kaplan-Meier<span class="def-item-dd-sep"></span></dd><dt id="def-item-24">LBCL<span class="def-item-dt-sep"></span></dt><dd>large B-cell lymphoma<span class="def-item-dd-sep"></span></dd><dt id="def-item-25">MAIC<span class="def-item-dt-sep"></span></dt><dd>matching adjusted indirect comparisons<span class="def-item-dd-sep"></span></dd><dt id="def-item-26">NCT<span class="def-item-dt-sep"></span></dt><dd>national clinical trial<span class="def-item-dd-sep"></span></dd><dt id="def-item-27">NHL<span class="def-item-dt-sep"></span></dt><dd>non-Hodgkin lymphoma<span class="def-item-dd-sep"></span></dd><dt id="def-item-28">NT<span class="def-item-dt-sep"></span></dt><dd>neurotoxicity<span class="def-item-dd-sep"></span></dd><dt id="def-item-29">OR<span class="def-item-dt-sep"></span></dt><dd>odds ratio<span class="def-item-dd-sep"></span></dd><dt id="def-item-30">ORR<span class="def-item-dt-sep"></span></dt><dd>objective response rate<span class="def-item-dd-sep"></span></dd><dt id="def-item-31">OS<span class="def-item-dt-sep"></span></dt><dd>overall survival<span class="def-item-dd-sep"></span></dd><dt id="def-item-32">PFS<span class="def-item-dt-sep"></span></dt><dd>progression free survival<span class="def-item-dd-sep"></span></dd><dt id="def-item-33">PH<span class="def-item-dt-sep"></span></dt><dd>proportional hazards<span class="def-item-dd-sep"></span></dd><dt id="def-item-34">PPCR<span class="def-item-dt-sep"></span></dt><dd>principles and practice of clinical research<span class="def-item-dd-sep"></span></dd><dt id="def-item-35">PRISMA<span class="def-item-dt-sep"></span></dt><dd>preferred reporting items for systematic reviews and meta-analyses<span class="def-item-dd-sep"></span></dd><dt id="def-item-36">R/R LBCL<span class="def-item-dt-sep"></span></dt><dd>relapsed/refractory large B-cell lymphoma<span class="def-item-dd-sep"></span></dd><dt id="def-item-37">RR<span class="def-item-dt-sep"></span></dt><dd>relative risk<span class="def-item-dd-sep"></span></dd><dt id="def-item-38">RS<span class="def-item-dt-sep"></span></dt><dd>Richter’s transformation<span class="def-item-dd-sep"></span></dd><dt id="def-item-39">scFv<span class="def-item-dt-sep"></span></dt><dd>single-chain variable fragment<span class="def-item-dd-sep"></span></dd><dt id="def-item-40">SD<span class="def-item-dt-sep"></span></dt><dd>stable disease<span class="def-item-dd-sep"></span></dd><dt id="def-item-41">TNF-α<span class="def-item-dt-sep"></span></dt><dd>tumor necrosis factor-α<span class="def-item-dd-sep"></span></dd><dt id="def-item-42">trDLBCL<span class="def-item-dt-sep"></span></dt><dd>transformed DLBCL<span class="def-item-dd-sep"></span></dd><dt id="def-item-43">ZUMA-1<span class="def-item-dt-sep"></span></dt><dd>name of Yescarta clinical trial</dd></dl></li></div><span class="highwire-journal-article-marker-end"></span></div><span class="related-urls"></span></div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-biorxiv-copyright" >
  
      
  
  <div class="pane-content">
    <div class="field field-name-field-highwire-copyright field-type-text field-label-inline clearfix"><div class="field-label">Copyright&nbsp;</div><div class="field-items"><div class="field-item even">The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.<span class="license-type"> It is made available under a <a href="http://creativecommons.org/licenses/by-nd/4.0/" class="" data-icon-position="" data-hide-link-title="0">CC-BY-ND 4.0 International license</a>.</span></div></div></div>  </div>

  
  </div>
</div>
  </div>
</div>
</div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-disqus-comment" >
  
      
  
  <div class="pane-content">
    <div id="disqus_thread"><noscript><p><a href="http://medRxiv.disqus.com/?url=https%3A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.1101%2F2021.10.24.21265450v1" class="" data-icon-position="" data-hide-link-title="0">View the discussion thread.</a></p></noscript></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-back-to-top" >
  
      
  
  <div class="pane-content">
    <a href="#page" class="back-to-top" data-icon-position="" data-hide-link-title="0"><span class="icon-chevron-up"></span> Back to top</a>  </div>

  
  </div>
</div>
			</div>
		</div>
		
		<div class="sidebar-right-wrapper grid-10 omega">
			<div class="panel-panel panel-region-sidebar-right">
			  <div class="inside"><div class="panel-pane pane-highwire-node-pager" >
  
      
  
  <div class="pane-content">
    <div class="pager highwire-pager pager-mini clearfix highwire-node-pager highwire-article-pager"><span class="pager-prev"><a href="/content/10.1101/2021.10.24.21265344v1" title="Impact of biologics and small molecules for Inflammatory Bowel Disease on COVID-19 Related Hospitalization: A Systematic Review and Meta-analysis" rel="prev" class="pager-link-prev link-icon"><span class="icon-circle-arrow-left"></span> <span class="title">Previous</span></a></span><span class="pager-next"><a href="/content/10.1101/2021.10.18.21264728v1" title="Brain Structure in Acutely Underweight and Partially Weight-Restored Individuals with Anorexia Nervosa - A Coordinated Analysis by the ENIGMA Eating Disorders Working Group" rel="next" class="pager-link-next link-icon-right link-icon"><span class="title">Next</span> <span class="icon-circle-arrow-right"></span></a></span></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-custom pane-1" >
  
      
  
  <div class="pane-content">
    Posted&nbsp;October 26, 2021.  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-panels-mini pane-biorxiv-art-tools" >
  
      
  
  <div class="pane-content">
    <div id="mini-panel-biorxiv_art_tools" class="highwire-2col-stacked panel-display">
	  
  <div class="panel-row-wrapper clearfix">
		<div class="content-left-wrapper content-column">
          <div class="panel-panel panel-region-content-left">
            <div class="inside"><div class="panel-pane pane-highwire-variant-link" >
  
      
  
  <div class="pane-content">
    <a href="/content/10.1101/2021.10.24.21265450v1.full.pdf" target="_self" class="article-dl-pdf-link link-icon"><span class="icon-external-link-sign"></span> <span class="title">Download PDF</span></a>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-biorxiv-supplementary-fragment" >
  
      
  
  <div class="pane-content">
    <p><a href="/content/10.1101/2021.10.24.21265450v1.supplementary-material?versioned=true"><i class="icon-file"></i>Supplementary Material </a></p>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-variant-link" >
  
      
  
  <div class="pane-content">
    <a href="/content/early/2021/10/26/2021.10.24.21265450.external-links" target="_self" class="link-icon"><span class="icon-file"></span> <span class="title">Data/Code</span></a>  </div>

  
  </div>
</div>
          </div>
        </div>
        
        <div class="content-right-wrapper content-column">
          <div class="panel-panel panel-region-content-right">
            <div class="inside"><div class="panel-pane pane-minipanel-dialog-link pane-biorxiv-art-email" >
  
      
  
  <div class="pane-content">
    <div class='minipanel-dialog-wrapper'><div class='minipanel-dialog-link-link'><a href="/" oncontextmenu="javascript: return false;" class="minipanel-dialog-link-trigger" title="Email this Article" data-icon-position="" data-hide-link-title="0"><i class = 'icon-envelope'></i> Email</a></div><div class='minipanel-dialog-link-mini' style='display:none'><div class="panel-display panel-1col clearfix" id="mini-panel-biorxiv_art_email">
  <div class="panel-panel panel-col">
    <div><div class="panel-pane pane-block pane-forward-form pane-forward" >
  
      
  
  <div class="pane-content">
    <form action="/content/10.1101/2021.10.24.21265450v1" method="post" id="forward-form" accept-charset="UTF-8"><div><div id="edit-instructions" class="form-item form-item-label-before form-type-item">
 <p>Thank you for your interest in spreading the word about medRxiv.</p><p>NOTE: Your email address is requested solely to identify you as the sender of this article.</p>
</div>
<div class="form-item form-item-label-before form-type-textfield form-item-email">
  <label for="edit-email">Your Email <span class="form-required" title="This field is required.">*</span></label>
 <input type="text" id="edit-email" name="email" value="" size="58" maxlength="256" class="form-text required" />
</div>
<div class="form-item form-item-label-before form-type-textfield form-item-name">
  <label for="edit-name">Your Name <span class="form-required" title="This field is required.">*</span></label>
 <input type="text" id="edit-name" name="name" value="" size="58" maxlength="256" class="form-text required" />
</div>
<div class="form-item form-item-label-before form-type-textarea form-item-recipients">
  <label for="edit-recipients">Send To <span class="form-required" title="This field is required.">*</span></label>
 <div class="form-textarea-wrapper resizable"><textarea id="edit-recipients" name="recipients" cols="50" rows="5" class="form-textarea required"></textarea></div>
<div class="description">Enter multiple addresses on separate lines or separate them with commas.</div>
</div>
<div id="edit-page" class="form-item form-item-label-before form-type-item">
  <label for="edit-page">You are going to email the following </label>
 <a href="/content/10.1101/2021.10.24.21265450v1" class="active" data-icon-position="" data-hide-link-title="0">Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Rev…</a>
</div>
<div id="edit-subject" class="form-item form-item-label-before form-type-item">
  <label for="edit-subject">Message Subject </label>
 (Your Name) has forwarded a page to you from medRxiv
</div>
<div id="edit-body" class="form-item form-item-label-before form-type-item">
  <label for="edit-body">Message Body </label>
 (Your Name) thought you would like to see this page from the medRxiv website.
</div>
<div class="form-item form-item-label-before form-type-textarea form-item-message">
  <label for="edit-message--2">Your Personal Message </label>
 <div class="form-textarea-wrapper resizable"><textarea id="edit-message--2" name="message" cols="50" rows="10" class="form-textarea"></textarea></div>
</div>
<input type="hidden" name="path" value="node/426533" />
<input type="hidden" name="path_cid" value="" />
<input type="hidden" name="forward_footer" value=" " />
<input type="hidden" name="form_build_id" value="form-UD3xQHXEr5TUon2kiiUPzFHkMYS4bSjrAX6ih_HBzjE" />
<input type="hidden" name="form_id" value="forward_form" />
<fieldset class="captcha form-wrapper"><legend><span class="fieldset-legend">CAPTCHA</span></legend><div class="fieldset-wrapper"><div class="fieldset-description">This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.</div><input type="hidden" name="captcha_sid" value="157694703" />
<input type="hidden" name="captcha_token" value="886ffc47b6a20386d7424bde2f2511e4" />
<input type="hidden" name="captcha_response" value="Google no captcha" />
<div class="g-recaptcha" data-sitekey="6LfnJVIUAAAAAE-bUOMg0MJGki4lqSvDmhJp19fN" data-theme="light" data-type="image"></div></div></fieldset>
<div class="form-actions form-wrapper" id="edit-actions"><input type="submit" id="edit-submit" name="op" value="Send Message" class="form-submit" /></div></div></form>  </div>

  
  </div>
</div>
  </div>
</div>
</div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-share-link highwire_clipboard_link_ajax"  id="shareit">
  
      
  
  <div class="pane-content">
    <a href="/" class="link-icon"><span class="icon-share-alt"></span> <span class="title">Share</span></a>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-panels-mini pane-biorxiv-share highwire_clipboard_form_ajax_shareit" >
  
      
  
  <div class="pane-content">
    
<div class="panel-display omega-12-onecol" id="mini-panel-biorxiv_share">

		  <div class="panel-panel grid-12 panel-region-preface">
		  <div class="inside"><div class="panel-pane pane-highwire-article-citation" >
  
      
  
  <div class="pane-content">
    <div class="highwire-article-citation highwire-citation-type-highwire-article node426533--3" data-node-nid="426533" id="node426533--41665600147" data-pisa="medrxiv;2021.10.24.21265450v1" data-pisa-master="medrxiv;2021.10.24.21265450" data-seqnum="426533" data-apath="/medrxiv/early/2021/10/26/2021.10.24.21265450.atom"><div  class="highwire-cite highwire-cite-highwire-article highwire-citation-biorxiv-article-pap-list clearfix" >

      <div class="highwire-cite-title" >
      <div class="highwire-cite-title">Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review</div>    </div>
  
      <div  class="highwire-cite-authors" ><span  class="highwire-citation-authors"><span class="highwire-citation-author first" data-delta="0"><span class="nlm-given-names">Bayarmagnai</span> <span class="nlm-surname">Weinstein</span></span>, <span class="highwire-citation-author" data-delta="1"><span class="nlm-given-names">Bogdan</span> <span class="nlm-surname">Muresan</span></span>, <span class="highwire-citation-author" data-delta="2"><span class="nlm-given-names">Sara</span> <span class="nlm-surname">Solano</span></span>, <span class="highwire-citation-author" data-delta="3"><span class="nlm-given-names">Antonio Vaz</span> <span class="nlm-surname">de Macedo</span></span>, <span class="highwire-citation-author" data-delta="4"><span class="nlm-given-names">YoonJung</span> <span class="nlm-surname">Lee</span></span>, <span class="highwire-citation-author" data-delta="5"><span class="nlm-given-names">Yu-Chen</span> <span class="nlm-surname">Su</span></span>, <span class="highwire-citation-author" data-delta="6"><span class="nlm-given-names">Yeseul</span> <span class="nlm-surname">Ahn</span></span>, <span class="highwire-citation-author" data-delta="7"><span class="nlm-given-names">Gabriela</span> <span class="nlm-surname">Henriquez</span></span>, <span class="highwire-citation-author" data-delta="8"><span class="nlm-given-names">Cristina</span> <span class="nlm-surname">Camargo</span></span>, <span class="highwire-citation-author" data-delta="9"><span class="nlm-given-names">Gwang-Jin</span> <span class="nlm-surname">Kim</span></span>, <span class="highwire-citation-author" data-delta="10"><span class="nlm-given-names">David O.</span> <span class="nlm-surname">Carpenter</span></span></span></div>
  
      <div  class="highwire-cite-metadata" ><span  class="highwire-cite-metadata-journal highwire-cite-metadata">medRxiv </span><span  class="highwire-cite-metadata-pages highwire-cite-metadata">2021.10.24.21265450; </span><span  class="highwire-cite-metadata-doi highwire-cite-metadata"><span class="doi_label">doi:</span> https://doi.org/10.1101/2021.10.24.21265450 </span></div>
  
  
  </div>
</div>  </div>

  
  </div>
</div>
	  </div>
	
  <div class="panel-panel grid-12 panel-region-content">
  	<div class="inside"><div class="panel-pane pane-highwire-article-clipboard-copy" >
  
      
  
  <div class="pane-content">
    <div class = "clipboard-copy">
  <span class="label-url">
    <label for="dynamic">Share This Article:</label>
  </span>
  <span class="input-text-url">
    <input type="text" id="dynamic" value="https://www.medrxiv.org/content/10.1101/2021.10.24.21265450v1" size="50"/>
  </span>
  <span class="copy-button button">
    <button id="copy-dynamic" class="clipboardjs-button" data-clipboard-target="#dynamic" data-clipboard-alert-style="tooltip" data-clipboard-alert-text="Copied!">Copy</button>
  </span>
</div>
  </div>

  
  </div>
</div>
  </div>
	
		  <div class="panel-panel grid-12 panel-region-postscript">
	    <div class="inside"><div class="panel-pane pane-service-links" >
  
      
  
  <div class="pane-content">
    <div class="service-links"><a href="http://digg.com/submit?phase=2&amp;url=https%3A//www.medrxiv.org/content/10.1101/2021.10.24.21265450v1&amp;title=Efficacy%20and%20Safety%20of%20Experimental%20Chimeric%20Antigen%20Receptor%20%28CAR%29%20T-cells%20versus%20Axicabtagene%20ciloleucel%20%28Yescarta%29%20for%20the%20Treatment%20of%20Relapsed/Refractory%20Large%20B-Cell%20Lymphoma%20%28LBCL%29%3A%20Matching%20Adjusted%20Indirect%20Comparisons%20%28MAICs%29%20and%20Systematic%20Rev%E2%80%A6" id="digg" title="Digg this post on digg.com" class="service-links-digg" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/digg.png" alt="Digg logo" /></a> <a href="http://reddit.com/submit?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.24.21265450v1&amp;title=Efficacy%20and%20Safety%20of%20Experimental%20Chimeric%20Antigen%20Receptor%20%28CAR%29%20T-cells%20versus%20Axicabtagene%20ciloleucel%20%28Yescarta%29%20for%20the%20Treatment%20of%20Relapsed/Refractory%20Large%20B-Cell%20Lymphoma%20%28LBCL%29%3A%20Matching%20Adjusted%20Indirect%20Comparisons%20%28MAICs%29%20and%20Systematic%20Rev%E2%80%A6" id="reddit" title="Submit this post on reddit.com" class="service-links-reddit" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/reddit.png" alt="Reddit logo" /></a> <a href="http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.24.21265450v1&amp;text=Efficacy%20and%20Safety%20of%20Experimental%20Chimeric%20Antigen%20Receptor%20%28CAR%29%20T-cells%20versus%20Axicabtagene%20ciloleucel%20%28Yescarta%29%20for%20the%20Treatment%20of%20Relapsed/Refractory%20Large%20B-Cell%20Lymphoma%20%28LBCL%29%3A%20Matching%20Adjusted%20Indirect%20Comparisons%20%28MAICs%29%20and%20Systematic%20Rev%E2%80%A6" id="twitter" title="Share this on Twitter" class="service-links-twitter" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png" alt="Twitter logo" /></a> <a href="http://www.citeulike.org/posturl?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.24.21265450v1&amp;title=Efficacy%20and%20Safety%20of%20Experimental%20Chimeric%20Antigen%20Receptor%20%28CAR%29%20T-cells%20versus%20Axicabtagene%20ciloleucel%20%28Yescarta%29%20for%20the%20Treatment%20of%20Relapsed/Refractory%20Large%20B-Cell%20Lymphoma%20%28LBCL%29%3A%20Matching%20Adjusted%20Indirect%20Comparisons%20%28MAICs%29%20and%20Systematic%20Rev%E2%80%A6" id="citeulike" title="Share on CiteULike" class="service-links-citeulike" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/citeyoulike.png" alt="CiteULike logo" /></a> <a href="http://www.facebook.com/sharer.php?u=https%3A//www.medrxiv.org/content/10.1101/2021.10.24.21265450v1&amp;t=Efficacy%20and%20Safety%20of%20Experimental%20Chimeric%20Antigen%20Receptor%20%28CAR%29%20T-cells%20versus%20Axicabtagene%20ciloleucel%20%28Yescarta%29%20for%20the%20Treatment%20of%20Relapsed/Refractory%20Large%20B-Cell%20Lymphoma%20%28LBCL%29%3A%20Matching%20Adjusted%20Indirect%20Comparisons%20%28MAICs%29%20and%20Systematic%20Rev%E2%80%A6" id="facebook" title="Share on Facebook" class="service-links-facebook" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png" alt="Facebook logo" /></a> <a href="http://www.google.com/bookmarks/mark?op=add&amp;bkmk=https%3A//www.medrxiv.org/content/10.1101/2021.10.24.21265450v1&amp;title=Efficacy%20and%20Safety%20of%20Experimental%20Chimeric%20Antigen%20Receptor%20%28CAR%29%20T-cells%20versus%20Axicabtagene%20ciloleucel%20%28Yescarta%29%20for%20the%20Treatment%20of%20Relapsed/Refractory%20Large%20B-Cell%20Lymphoma%20%28LBCL%29%3A%20Matching%20Adjusted%20Indirect%20Comparisons%20%28MAICs%29%20and%20Systematic%20Rev%E2%80%A6" id="google" title="Bookmark this post on Google" class="service-links-google" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/google-32.png" alt="Google logo" /></a> <a href="http://www.mendeley.com/import/?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.24.21265450v1&amp;title=Efficacy%20and%20Safety%20of%20Experimental%20Chimeric%20Antigen%20Receptor%20%28CAR%29%20T-cells%20versus%20Axicabtagene%20ciloleucel%20%28Yescarta%29%20for%20the%20Treatment%20of%20Relapsed/Refractory%20Large%20B-Cell%20Lymphoma%20%28LBCL%29%3A%20Matching%20Adjusted%20Indirect%20Comparisons%20%28MAICs%29%20and%20Systematic%20Rev%E2%80%A6" id="mendeley" title="Share on Mendeley" class="service-links-mendeley" rel="nofollow" data-icon-position="" data-hide-link-title="0"><img src="https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png" alt="Mendeley logo" /></a></div>  </div>

  
  </div>
</div>
	  </div>
	
</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-minipanel-dialog-link pane-biorxiv-cite-tool" >
  
      
  
  <div class="pane-content">
    <div class='minipanel-dialog-wrapper'><div class='minipanel-dialog-link-link'><a href="/" oncontextmenu="javascript: return false;" class="minipanel-dialog-link-trigger link-icon" title="Citation Tools"><span class="icon-globe"></span> <span class="title">Citation Tools</span></a></div><div class='minipanel-dialog-link-mini' style='display:none'><div class="panel-display panel-1col clearfix" id="mini-panel-biorxiv_cite_tool">
  <div class="panel-panel panel-col">
    <div><div class="panel-pane pane-highwire-citation-export" >
  
      
  
  <div class="pane-content">
    <div class="highwire-citation-export">  
  <div class="highwire-citation-info">
      <div class="highwire-article-citation highwire-citation-type-highwire-article node426533--5" data-node-nid="426533" id="node426533--61898223613" data-pisa="medrxiv;2021.10.24.21265450v1" data-pisa-master="medrxiv;2021.10.24.21265450" data-seqnum="426533" data-apath="/medrxiv/early/2021/10/26/2021.10.24.21265450.atom"><div  class="highwire-cite highwire-cite-highwire-article highwire-citation-biorxiv-article-pap-list clearfix" >

      <div class="highwire-cite-title" >
      <div class="highwire-cite-title">Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review</div>    </div>
  
      <div  class="highwire-cite-authors" ><span  class="highwire-citation-authors"><span class="highwire-citation-author first" data-delta="0"><span class="nlm-given-names">Bayarmagnai</span> <span class="nlm-surname">Weinstein</span></span>, <span class="highwire-citation-author" data-delta="1"><span class="nlm-given-names">Bogdan</span> <span class="nlm-surname">Muresan</span></span>, <span class="highwire-citation-author" data-delta="2"><span class="nlm-given-names">Sara</span> <span class="nlm-surname">Solano</span></span>, <span class="highwire-citation-author" data-delta="3"><span class="nlm-given-names">Antonio Vaz</span> <span class="nlm-surname">de Macedo</span></span>, <span class="highwire-citation-author" data-delta="4"><span class="nlm-given-names">YoonJung</span> <span class="nlm-surname">Lee</span></span>, <span class="highwire-citation-author" data-delta="5"><span class="nlm-given-names">Yu-Chen</span> <span class="nlm-surname">Su</span></span>, <span class="highwire-citation-author" data-delta="6"><span class="nlm-given-names">Yeseul</span> <span class="nlm-surname">Ahn</span></span>, <span class="highwire-citation-author" data-delta="7"><span class="nlm-given-names">Gabriela</span> <span class="nlm-surname">Henriquez</span></span>, <span class="highwire-citation-author" data-delta="8"><span class="nlm-given-names">Cristina</span> <span class="nlm-surname">Camargo</span></span>, <span class="highwire-citation-author" data-delta="9"><span class="nlm-given-names">Gwang-Jin</span> <span class="nlm-surname">Kim</span></span>, <span class="highwire-citation-author" data-delta="10"><span class="nlm-given-names">David O.</span> <span class="nlm-surname">Carpenter</span></span></span></div>
  
      <div  class="highwire-cite-metadata" ><span  class="highwire-cite-metadata-journal highwire-cite-metadata">medRxiv </span><span  class="highwire-cite-metadata-pages highwire-cite-metadata">2021.10.24.21265450; </span><span  class="highwire-cite-metadata-doi highwire-cite-metadata"><span class="doi_label">doi:</span> https://doi.org/10.1101/2021.10.24.21265450 </span></div>
  
  
  </div>
</div>  </div>
  <div class="highwire-citation-formats">
  	      <h2>Citation Manager Formats</h2>
        <div class="highwire-citation-formats-links">
      <span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.spage&amp;rft.epage&amp;rft.atitle=Efficacy%20and%20Safety%20of%20Experimental%20Chimeric%20Antigen%20Receptor%20%28CAR%29%20T-cells%20versus%20Axicabtagene%20ciloleucel%20%28Yescarta%29%20for%20the%20Treatment%20of%20Relapsed/Refractory%20Large%20B-Cell%20Lymphoma%20%28LBCL%29%3A%20Matching%20Adjusted%20Indirect%20Comparisons%20%28MAICs%29%20and%20Systematic%20Rev%E2%80%A6&amp;rft.volume&amp;rft.issue&amp;rft.date=2021-01-01%2000%3A00%3A00&amp;rft.stitle&amp;rft.jtitle=medRxiv&amp;rft.au=Weinstein%2C+Bayarmagnai&amp;rft.au=Muresan%2C+Bogdan&amp;rft.au=Solano%2C+Sara&amp;rft.au=de+Macedo%2C+Antonio+Vaz&amp;rft.au=Lee%2C+YoonJung&amp;rft.au=Su%2C+Yu-Chen&amp;rft.au=Ahn%2C+Yeseul&amp;rft.au=Henriquez%2C+Gabriela&amp;rft.au=Camargo%2C+Cristina&amp;rft.au=Kim%2C+Gwang-Jin&amp;rft.au=Carpenter%2C+David+O."></span><ul class="hw-citation-links inline button button-alt button-grid clearfix"><li class="bibtext first"><a href="/highwire/citation/426533/bibtext" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">BibTeX</a></li><li class="bookends"><a href="/highwire/citation/426533/bookends" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Bookends</a></li><li class="easybib"><a href="/highwire/citation/426533/easybib" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">EasyBib</a></li><li class="endnote-tagged"><a href="/highwire/citation/426533/endnote-tagged" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">EndNote (tagged)</a></li><li class="endnote-8-xml"><a href="/highwire/citation/426533/endnote-8-xml" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">EndNote 8 (xml)</a></li><li class="medlars"><a href="/highwire/citation/426533/medlars" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Medlars</a></li><li class="mendeley"><a href="/highwire/citation/426533/mendeley" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Mendeley</a></li><li class="papers"><a href="/highwire/citation/426533/papers" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Papers</a></li><li class="refworks-tagged"><a href="/highwire/citation/426533/refworks-tagged" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">RefWorks Tagged</a></li><li class="reference-manager"><a href="/highwire/citation/426533/reference-manager" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Ref Manager</a></li><li class="ris"><a href="/highwire/citation/426533/ris" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">RIS</a></li><li class="zotero last"><a href="/highwire/citation/426533/zotero" class="hw-download-citation-link" data-icon-position="" data-hide-link-title="0">Zotero</a></li></ul>    </div>
  </div>
</div>
  </div>

  
  </div>
</div>
  </div>
</div>
</div></div>  </div>

  
  </div>
</div>
          </div>
        </div>
	</div> <!-- /.panel-row-wrapper -->	
	
	</div>

  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-service-links" >
  
      
  
  <div class="pane-content">
    <div class="service-links"><div class="item-list"><ul><li class="first"><a href="http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.1101/2021.10.24.21265450v1&amp;count=horizontal&amp;via=&amp;text=Efficacy%20and%20Safety%20of%20Experimental%20Chimeric%20Antigen%20Receptor%20%28CAR%29%20T-cells%20versus%20Axicabtagene%20ciloleucel%20%28Yescarta%29%20for%20the%20Treatment%20of%20Relapsed/Refractory%20Large%20B-Cell%20Lymphoma%20%28LBCL%29%3A%20Matching%20Adjusted%20Indirect%20Comparisons%20%28MAICs%29%20and%20Systematic%20Rev%E2%80%A6&amp;counturl=https%3A//www.medrxiv.org/content/10.1101/2021.10.24.21265450v1" class="twitter-share-button service-links-twitter-widget" id="twitter_widget" title="Tweet This" rel="nofollow" data-icon-position="" data-hide-link-title="0"><span class="element-invisible">Tweet Widget</span></a></li><li><a href="http://www.facebook.com/plugins/like.php?href=https%3A//www.medrxiv.org/content/10.1101/2021.10.24.21265450v1&amp;layout=button_count&amp;show_faces=false&amp;action=like&amp;colorscheme=light&amp;width=100&amp;height=21&amp;font=&amp;locale=" id="facebook_like" title="I Like it" class="service-links-facebook-like" rel="nofollow" data-icon-position="" data-hide-link-title="0"><span class="element-invisible">Facebook Like</span></a></li><li class="last"><a href="https://www.medrxiv.org/content/10.1101/2021.10.24.21265450v1" id="google_plus_one" title="Plus it" class="service-links-google-plus-one" rel="nofollow" data-icon-position="" data-hide-link-title="0"><span class="element-invisible">Google Plus One</span></a></li></ul></div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-article-collections" >
  
        <h2 class="pane-title">Subject Area</h2>
    
  
  <div class="pane-content">
    <div class="highwire-list-wrapper highwire-article-collections"><div class="highwire-list"><ul class="highwire-article-collection-term-list"><li class="first last odd"><span class="highwire-article-collection-term"><a href="/collection/oncology" class="highlight" data-icon-position="" data-hide-link-title="0">Oncology<i class="icon-caret-right"></i>
</a></span></li></ul></div></div>  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-panels-mini pane-biorxiv-subject-collections block-style-col2" >
  
      
  
  <div class="pane-content">
    <div class="panel-flexible panels-flexible-8 clearfix" id="mini-panel-biorxiv_subject_collections">
<div class="panel-flexible-inside panels-flexible-8-inside">
<div class="panels-flexible-region panels-flexible-region-8-center panels-flexible-region-first panels-flexible-region-last">
  <div class="inside panels-flexible-region-inside panels-flexible-region-8-center-inside panels-flexible-region-inside-first panels-flexible-region-inside-last">
<div class="panel-pane pane-snippet" >
  
      
  
  <div class="pane-content">
    <div class="snippet biorxiv-subject-areas-table-title" id="biorxiv-subject-areas-table-title">
  
      
  <div class="snippet-content">
    <b>Subject Areas</b>  </div>

</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-snippet" >
  
      
  
  <div class="pane-content">
    <div class="snippet biorxiv-subject-areas-view-papers" id="biorxiv-subject-areas-view-papers">
  
      
  <div class="snippet-content">
    <a href="/content/early/recent"><strong>All Articles</strong></a>  </div>

</div>
  </div>

  
  </div>
<div class="panel-separator"></div><div class="panel-pane pane-highwire-subject-collections" >
  
      
  
  <div class="pane-content">
    <ul id="collection" class="collection highwire-list-expand"><li class="outer collection depth-2  child first"><div class = "data-wrapper"><a href="/collection/addiction-medicine" class="" data-icon-position="" data-hide-link-title="0">Addiction Medicine</a> <span class = "article-count">(111)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/allergy-and-immunology" class="" data-icon-position="" data-hide-link-title="0">Allergy and Immunology</a> <span class = "article-count">(299)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/anesthesia" class="" data-icon-position="" data-hide-link-title="0">Anesthesia</a> <span class = "article-count">(75)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/cardiovascular-medicine" class="" data-icon-position="" data-hide-link-title="0">Cardiovascular Medicine</a> <span class = "article-count">(665)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/dentistry-and-oral-medicine" class="" data-icon-position="" data-hide-link-title="0">Dentistry and Oral Medicine</a> <span class = "article-count">(121)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/dermatology" class="" data-icon-position="" data-hide-link-title="0">Dermatology</a> <span class = "article-count">(77)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/emergency-medicine" class="" data-icon-position="" data-hide-link-title="0">Emergency Medicine</a> <span class = "article-count">(216)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease" class="" data-icon-position="" data-hide-link-title="0">Endocrinology (including Diabetes Mellitus and Metabolic Disease)</a> <span class = "article-count">(299)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/epidemiology" class="" data-icon-position="" data-hide-link-title="0">Epidemiology</a> <span class = "article-count">(7268)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/forensic-medicine" class="" data-icon-position="" data-hide-link-title="0">Forensic Medicine</a> <span class = "article-count">(4)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/gastroenterology" class="" data-icon-position="" data-hide-link-title="0">Gastroenterology</a> <span class = "article-count">(306)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/genetic-and-genomic-medicine" class="" data-icon-position="" data-hide-link-title="0">Genetic and Genomic Medicine</a> <span class = "article-count">(1295)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/geriatric-medicine" class="" data-icon-position="" data-hide-link-title="0">Geriatric Medicine</a> <span class = "article-count">(126)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/health-economics" class="" data-icon-position="" data-hide-link-title="0">Health Economics</a> <span class = "article-count">(308)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/health-informatics" class="" data-icon-position="" data-hide-link-title="0">Health Informatics</a> <span class = "article-count">(1004)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/health-policy" class="" data-icon-position="" data-hide-link-title="0">Health Policy</a> <span class = "article-count">(526)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/health-systems-and-quality-improvement" class="" data-icon-position="" data-hide-link-title="0">Health Systems and Quality Improvement</a> <span class = "article-count">(359)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/hematology" class="" data-icon-position="" data-hide-link-title="0">Hematology</a> <span class = "article-count">(151)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/hiv-aids" class="" data-icon-position="" data-hide-link-title="0">HIV/AIDS</a> <span class = "article-count">(287)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/infectious_diseases" class="" data-icon-position="" data-hide-link-title="0">Infectious Diseases (except HIV/AIDS)</a> <span class = "article-count">(8512)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/intensive-care-and-critical-care-medicine" class="" data-icon-position="" data-hide-link-title="0">Intensive Care and Critical Care Medicine</a> <span class = "article-count">(483)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/medical-education" class="" data-icon-position="" data-hide-link-title="0">Medical Education</a> <span class = "article-count">(160)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/medical-ethics" class="" data-icon-position="" data-hide-link-title="0">Medical Ethics</a> <span class = "article-count">(40)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/nephrology" class="" data-icon-position="" data-hide-link-title="0">Nephrology</a> <span class = "article-count">(153)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/neurology" class="" data-icon-position="" data-hide-link-title="0">Neurology</a> <span class = "article-count">(1239)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/nursing" class="" data-icon-position="" data-hide-link-title="0">Nursing</a> <span class = "article-count">(63)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/nutrition" class="" data-icon-position="" data-hide-link-title="0">Nutrition</a> <span class = "article-count">(200)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/obstetrics-and-gynecology" class="" data-icon-position="" data-hide-link-title="0">Obstetrics and Gynecology</a> <span class = "article-count">(255)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/occupational-and-environmental-health" class="" data-icon-position="" data-hide-link-title="0">Occupational and Environmental Health</a> <span class = "article-count">(368)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/oncology" class="" data-icon-position="" data-hide-link-title="0">Oncology</a> <span class = "article-count">(702)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/ophthalmology" class="" data-icon-position="" data-hide-link-title="0">Ophthalmology</a> <span class = "article-count">(217)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/orthopedics" class="" data-icon-position="" data-hide-link-title="0">Orthopedics</a> <span class = "article-count">(70)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/otolaryngology" class="" data-icon-position="" data-hide-link-title="0">Otolaryngology</a> <span class = "article-count">(139)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/pain-medicine" class="" data-icon-position="" data-hide-link-title="0">Pain Medicine</a> <span class = "article-count">(73)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/palliative-medicine" class="" data-icon-position="" data-hide-link-title="0">Palliative Medicine</a> <span class = "article-count">(30)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/pathology" class="" data-icon-position="" data-hide-link-title="0">Pathology</a> <span class = "article-count">(195)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/pediatrics" class="" data-icon-position="" data-hide-link-title="0">Pediatrics</a> <span class = "article-count">(410)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/pharmacology-and-therapeutics" class="" data-icon-position="" data-hide-link-title="0">Pharmacology and Therapeutics</a> <span class = "article-count">(195)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/primary-care-research" class="" data-icon-position="" data-hide-link-title="0">Primary Care Research</a> <span class = "article-count">(158)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/psychiatry-and-clinical-psychology" class="" data-icon-position="" data-hide-link-title="0">Psychiatry and Clinical Psychology</a> <span class = "article-count">(1369)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/public-and-global-health" class="" data-icon-position="" data-hide-link-title="0">Public and Global Health</a> <span class = "article-count">(3057)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/radiology-and-imaging" class="" data-icon-position="" data-hide-link-title="0">Radiology and Imaging</a> <span class = "article-count">(509)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/rehabilitation-medicine-and-physical-therapy" class="" data-icon-position="" data-hide-link-title="0">Rehabilitation Medicine and Physical Therapy</a> <span class = "article-count">(244)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/respiratory-medicine" class="" data-icon-position="" data-hide-link-title="0">Respiratory Medicine</a> <span class = "article-count">(415)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/rheumatology" class="" data-icon-position="" data-hide-link-title="0">Rheumatology</a> <span class = "article-count">(158)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/sexual-and-reproductive-health" class="" data-icon-position="" data-hide-link-title="0">Sexual and Reproductive Health</a> <span class = "article-count">(118)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/sports-medicine" class="" data-icon-position="" data-hide-link-title="0">Sports Medicine</a> <span class = "article-count">(115)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/surgery" class="" data-icon-position="" data-hide-link-title="0">Surgery</a> <span class = "article-count">(153)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/toxicology" class="" data-icon-position="" data-hide-link-title="0">Toxicology</a> <span class = "article-count">(32)</span></div></li>
<li class="outer collection depth-2  child"><div class = "data-wrapper"><a href="/collection/transplantation" class="" data-icon-position="" data-hide-link-title="0">Transplantation</a> <span class = "article-count">(67)</span></div></li>
<li class="outer collection depth-2  child last"><div class = "data-wrapper"><a href="/collection/urology" class="" data-icon-position="" data-hide-link-title="0">Urology</a> <span class = "article-count">(51)</span></div></li>
</ul>  </div>

  
  </div>
  </div>
</div>
</div>
</div>
  </div>

  
  </div>
</div>
			</div>
		</div>
	
	</div> <!-- /.panel-row-wrapper -->	
	
	</div>

    </div>
  </div>
</div>      </div>
</div>  </div>
</section>    
  
  </div>    <div class="region region-page-bottom" id="region-page-bottom">
  <div class="region-inner region-page-bottom-inner">
      </div>
</div><script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__Vh5BcRYb6VtLoN3uam6O4DIKltYUVMjVDWtakoysPq0__Wed8jsPTirEozek7dWSCS8970Cp7a9xKKgFk6FPuSVM__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.js"></script>
<script type="text/javascript" src="https://d33xdlntwy0kbs.cloudfront.net/cshl_custom_medrxiv.js"></script>
<script type="text/javascript" src="https://www.medrxiv.org/sites/default/files/advagg_js/js__BmqjBnkz3MgYCAoc25s1lDRMEjLhC3mEPVonUFIHi08__Unwv5-ZIuHBfFwytsjEx1niBVJ7n1T4lPws7VrkHXM4__OWu9jWxbqz5eMqeTDc4xZhOzPlgoEqGh5PmxOqlf8ZY.js"></script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
function euCookieComplianceLoadScripts() {}
//--><!]]>
</script>
<script type="text/javascript">
<!--//--><![CDATA[//><!--
var eu_cookie_compliance_cookie_name = "";
//--><!]]>
</script>
  </body>
</html>
